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ABSTRACT
Introduction: Xerostomia and reduced salivary flow have been reported often enough
among HIV positive patients. Strong associations have also been established between
HIV infection and oral effects of reduced salivary flow like xerostomia, high DMFT,
increased candidial infection etc. Besides the direct effect of HIV infection,
xerostomia and reduced salivary flow have also been reported as a side effect of
Highly Active Anti Retroviral Treatment (HAART). Studies have shown that
xerostomia has a negative effect on the quality of life of people living with HIV &
AIDS. Although reduced salivary flow is a main cause for xerostomia, complaints of
xerostomia is also found in the absence of salivary flow deficiency. An exact
correlation between the two is not always found.
Aim: The aim of this study is to compare the prevalence of xerostomia and
hyposalivation, in HIV positive patients on HAART, HIV positive patients not on
HAART and HIV negative patients, attending Empilweni Gompo community health
centre (EGCHC) in East London.
Study Methods: This is a cross sectional analytical study. Xerostomia and resting &
chewing-stimulated salivary flow rates were measured for 150 patients who were from
three groups: group 1- HIV negative, group 2- HIV positive not on HAART and group
3- HIV positive on HAART for more than two years. Each group had 50 patients.
Xerostomia was measured using a questionnaire and salivary flow rates were
calculated after saliva collection over a  three minute period.
Results: There was significant difference in the prevalences for xerostomia (p=0.006)
and less than normal chewing-stimulated flow rate (p=0.041) among the three groups
with the HIV positive group not on HAART showing the greatest deficiency. HAART
was not found to have a negative effect on salivary function. A statistical significance
was also observed while comparing mean resting (p=0.010) and chewing-stimulated
(p=0.034) salivary flow rates among the three groups. The mean salivary flow rate of
those complaining of xerostomia was found to be significantly lower than that of those
who did not have xerostomia (p=0.005).
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Conclusion: HIV positive patients not on HAART are more vulnerable to salivary
gland dysfunction. HAART in itself does not to adversely affect xerostomic
perceptions or salivary flow rates. The xerostomia questionnaire is a useful tool in
indicating those with possible low salivary flow rates.
Key words: HIV, Salivary gland hypofunction, Xerostomia, HAART, Salivary flow
rate, Saliva collection.
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1CHAPTER - 1
INTRODUCTION
According to the Human Sciences Research Council's (HSRC) National HIV
Prevalence, Incidence and Behaviour Survey that was released in April 2014, South
Africa ranks first in HIV incidence in the world (Shisana et al., 2014). The number of
South Africans infected with HIV now stands at 6.4-million; 12.2% of the population.
This is an increase of 1.2 million more than in 2008. The HSRC attributes this increase
in prevalence “largely due to the combined effects of new infections and a successfully
expanded ART programme. The latter has increased survival among HIV-infected
individuals” (Shisana et al., 2014).
Since the early days of its emergence, HIV has been associated with a variety of oral
lesions. Klein et al. (1984) were among the first to observe and associate the presence
of oral candidial infections to the subsequent development of AIDS. There has been a
general decrease in oral manifestations related to HIV in patients on HAART
(Greenspan et al., 2004; Schmidt-Westhausen et al., 2000; Masiiwa and Naidoo, 2011;
Ortega et al., 2009). Oral changes seen in HIV positive patients on HAART were the
reduction of candidiasis, hairy leukoplakia and Kaposi’s sarcoma. (Nittayananta et al.,
2010a; Schmidt-Westhaussen et al., 2000; Hamza et al., 2006).
HIV-associated Salivary Gland Disease (HIV-SGD) in general seems to be slowly
increasing in prevalence during the post HAART era (Greenspan et al., 2001; Patton et
al., 2000). A higher prevalence of 50% and 47% for HIV-SGD has been reported from
Africa (Naidoo and Chikte, 2004; Matee et al., 2000). An increase in salivary gland
disease was also reported in a cohort with established use of HAART (Patton et al.,
2000; Freeman et al., 2012). Reduced salivary flow or xerostomia was also reported
with the use of HAART (Freeman et al., 2012; Navazesh et al., 2003; Nittayananta
2010a).
The most common salivary gland changes relate to their function of saliva production
and manifest as xerostomia and hyposalivation. Xerostomia is the perceived feeling of
dry mouth which may or may not be associated with salivary gland hypofunction. It is
subjective and can be measured by means of questionnaires (Sreebny & Valdini, 1988)
 
 
 
 
2or visual analogue scales (Pai et al., 2001). On the other hand, hyposalivation is a
demonstrable reduction in salivary flow rate that can be measured objectively by
collecting saliva over a specified period of time (Navazesh et al., 1992a). Often these
terms have been used interchangeably but studies have demonstrated that a report of
xerostomia does not necessarily indicate an actual measurable reduction in salivary
flow rate. The reverse is also true, as a few of the patients that did show reduced flow
rates did not complain of dry mouth symptoms (Sreebny & Valdini, 1988).
A reduction in salivary flow rates would adversely affect its functions which include
lubrication, buffering capacity, tooth remineralisation, antimicrobial and antifungal
protection. This would result in an increase in dental caries, certain oral infections and
a general oral discomfort. Difficulty in denture retention is often experienced by those
with low salivary flow rates. Salivary gland hypofunction also has a high predictive
value for recurrent candidial infection (McCarthy et al., 1991). Busato et al. (2013), in
their study, concluded that xerostomia reduces the quality of life of people living with
HIV & AIDS
With HIV infection being progressively managed successfully by the country’s health
care services, more and more HIV infected people are living longer and healthier lives
while on HAART. Therefore, it is imperative that the general dental practitioner be
aware of the salivary gland effects and resultant oral consequences seen in HIV
infection and subsequent HAART.
These factors, along with the fact that little data is available from South Africa on the
long term effects of HAART on the oral health of this increasing population subset,
has been a motivation for this study.
The present study evaluates and compares the prevalence of self reported xerostomia
through a questionnaire (Sreebny & Valdini, 1988) and the prevalence of
hyposalivation through measuring salivary flow rates as described by Navazesh et al.,
(1992a, 2003) among 3 sub groups: HIV positive on long term HAART, HIV positive
not on HAART and HIV negative individuals.
 
 
 
 
3CHAPTER-2
LITERATURE REVIEW
The basis of knowledge required for this review will begin by defining the normal
physiological responses of the salivary glands and the saliva they produce. This will
enable a concise evaluation and understanding of the loss of this function and the
sequelae thereof. The literature review begins with a summary of studies and review
articles that have accrued the knowledge that is currently available. Having understood
the physiological characteristics and functions of normal salivary mechanisms,
subjective and objective ways to assess its health is also reviewed.
The effect of systemic disease, especially HIV infection, and HAART, on the salivary
mechanism will be explored followed by ways to alleviate salivary gland dysfunction
to complete a holistic review on this topic.
2.1. SALIVARY GLANDS AND SALIVA
Saliva is an exocrine secretion that is produced by 3 major and numerous minor
salivary glands. The paired major salivary glands - parotid, submandibular and
sublingual, secrete about 90% of the total volume of saliva (Napeñas et al., 2009). The
sublingual and submandibular glands are located in the floor of the mouth. Minor
salivary glands are found all over the mouth: palate, lower lip, tongue, cheek and
pharynx. While the parotid glands produce mostly serous secretions, the sublingual
and the minor salivary glands produce purely mucous secretions and the
submandibular produces a mixed sero-mucous secretion (Cassolato & Turnbull, 2003).
Saliva is a slightly acidic, hypotonic complex mix of oral secretions composed of 90%
water. Some of the important constituents of saliva include electrolytes,
immunoglobulins, nitrogenous products, enzymes and other proteins.
Each of the many components in saliva plays an important function in maintaining the
oral homeostasis. These constituents impose an arsenal of protective functions that are
depicted in greater detail in Table-2.1.
 
 
 
 
4Table 2.1- Functions and components of saliva
Functions Component in saliva
Protection of teeth and oral, pharyngeal and oesophageal mucosa
Mechanical cleansing of teeth and mucosa
Lubrication of teeth and mucosa
Keep oral mucosa intact, soft and moistened
Prevent tooth demineralisation
Buffer capacity
Water
Water, mucins
Water, mucins, salts, epidermal growth
factor, fibroblast growth factor, nerve
growth factor
Proline-rich proteins, statherins cystatins,
histatins, calcium and phosphate
Bicarbonate, phosphate and protein
Antimicrobial activities
Antibacterial functions
Fungicidal functions
Antiviral functions
Amylases, cystatins, histatins, mucins,
peroxidase, lysozyme, lactoferrin,
calprotectin, immunoglobulins,
chromogranin A.
Histatins, immunoglobulins, chromogranin A
Cystatins, mucins, immunoglobulins
Digestive properties
Formation of food bolus
Facilitation of mastication and swallowing
Initial digestion
Dissolution of taste compounds
Water, mucins
Water and, mucins
α-amylases, lipases, ribonucleases,
proteases, water, mucins
Gustin (carbonanhydrase), zinc (Zn2+),water
Facilitation of speech Water, mucins
Adapted from- AML Pedersen. 2007, “Saliva”, Zendium, available from
<http://www.zendium.dk/Files/zendium.dk/material/publikationer/saliva.pdf>
Mucins are vital in providing lubrication for speech, mastication and deglutination
(Mandel, 1989). Antibacterial, antiviral and antifungal components like lactoferrins,
lysozymes, histatins, salivary protease inhibitors, immunoglobulins etc. are important
in providing host defence in the oral cavity (Mandel, 1989, Humphrey & Williamson,
 
 
 
 
52001). Electrolytes maintain pH, buffering and re-mineralization of enamel. Lavarge
or mechanical cleansing action is brought about by water, which provides for the
quantitative bulk of saliva.
In a healthy adult, an average of 800ml to 1.5 litres of saliva is produced daily (Hall,
2010). During the resting phase, 65% unstimulated saliva is produced by the
submandibular gland, 20% by the parotid, 7-8% from the sub-lingual and the
remaining from minor salivary glands. More than 50% of the saliva produced under
stimulation is from the parotid gland (De Almeida et al., 2008). Ericsson & Hardwick
(1978) classified whole saliva secretory rates as very low, low and normal. A normal
resting flow is between 0.25ml and 0.35 ml per minute and a normal stimulated
salivary flow rate is between 1ml to 3ml per minute. Salivary flow rates can vary
among persons. A community based study by Yeh et al. (1998) showed that both
resting and stimulated salivary flow reduced with age. This finding was also reported
by Toida et al. (2010) in a large study population of 1188 adults. Although there is
histological evidence of glandular parenchymal changes with increasing age, a number
of studies have reported a decline only in the unstimulated flow rate and no significant
reduction in the stimulated flow rate (Yeh et al., 1998; Percival et. al., 1994; Navazesh
et. al., 1992b; Osterberg et. al., 1984). It appears that the submandibular salivary
glands are more affected by age and or the parotid gland has a good response capacity.
Most of the above studies show a decrease in salivary flow among females. This could
possibly be due to the fact that males have submandibular glands that are up to 50%
larger than those in females (Scott, 1975).
Nagler and Hershkovich (2005), in their age related study of salivary flow rates, found
a significant increase in the concentration of some salivary components like protein,
amylase, lactate dehydrogenase, IgA, IgG, potassium, chloride, phosphorus, calcium,
magnesium and uric acid in the older age group (70 – 86 yrs). Although the
concentrations were high, when the reduced salivary flow rate was taken into account,
there was a significant reduction in the actual output of proteins, lactate
dehydrogenase, IgA, IgG, sodium, calcium and magnesium. In addition to a decrease
in the volume of saliva, the reduction in the total amount of available salivary
components further compromises the protective functions of saliva and may account
for an increase in oral diseases in the elderly (Nagler and Hershkovich, 2005). Age
 
 
 
 
6related reduction in salivary mucin concentration in individuals above the age of 65
has also been recorded (Denny et al., 1991; Navazesh et al., 1992b).
Ship et al. in 1995 did not see any age or gender related changes in salivary flow in
healthy, non-medicated individuals. In 1993, Wu & Ship proposed that aging does not
affect salivary gland flow, per say, but a reduction in salivary gland function,
especially in the submandibular gland is due to increasing systemic problems and
associated poly-medication. “The submandibular gland may be more sensitive to
physiologic permutations than the parotid gland.” (Wu & Ship, 1993). A possible
reason why the complaints of xerostomia increase with age, even though there is no
actual reduction in salivary flow, is due to reduced concentration of mucins. Mucin
production by minor salivary glands is important in lubrication of the oral cavity, and
reduced concentrations of it can be perceived as dry mouth (Navazesh et. al., 1992b).
A Swedish study on 1427 people, by Flink et al., (2008) has shown that the prevalence
of hyposalivation among the different age groups did not vary much until the age of 50
for women and 60 for men. There is a consensus that advanced age cause changes to
salivary gland physiology.
Apart from inter-individual differences, salivary flow rates show up to 45% intra-
individual variations. (Ghezzi et. al., 2000) This is due to circadian (Dawes, 1972)
changes. Hydration can also influence flow rate in a healthy individual (Ship and
Fisher, 1997). All saliva collection in this study was done between 9am and 3pm and
all patients were requested not to drink or eat for 90 minutes before saliva collection.
 
 
 
 
72.2. SALIVARY GLAND HYPOFUNCTION
The term “salivary gland hypofunction” may be used to cover xerostomia,
hyposalivation and salivary compositional changes (Nederfors, 2000) A more updated
definition should also include other oral sensory changes like burning mouth and taste
dysgeusia. Each of these inter-related entities can exist together or independent of each
other; making a co-relation difficult to establish.
2.2.1 Xerostomia
Xerostomia is the perceived feeling of dry mouth. The causes encompass those of
salivary gland origin, and those that are not of salivary gland origin. Although a strong
co-relation exists between xerostomia and reduced salivary flow rate (Osterberg et al.,
1984; Farsi, 2007), it may not always be the cause of xerostomia (Sreebny & Valdini,
1988; Fox et al., 1987; Toida et. al., 2010).
Alterations in salivary composition, in particular, glycoproteins like mucins, can also
cause patients to report xerostomia. Mucins provide a moistening and lubricating
function, and a reduction in mucin can increase the symptoms of mucosal dryness
(Mandel, 1989, Navazesh et al., 1992b). All the etiological causes for reduced salivary
flow (listed in table 2.2) can also be considered as salivary causes for xerostomia.
Non-salivary causes for xerostomia include dehydration, mouth breathing, cognitive
alteration and psychological disorders (Fox, 1996). Atkinson et al. (2005) suggested
that xerostomia complaints may not necessarily be due to hyposalivation, but could
reflect dehydration or other systemic conditions. Narhi (1994) and Fox et al., (1987)
have proposed that, since perception of oral dryness is related to mucosal dehydration,
non-uniform wetting of the mouth or localised areas of dryness can increase
xerostomic perception.
 
 
 
 
8Table 2.2 – Causes of Salivary Gland Hypofunction and Xerostomia
1. Water/Electrolyte loss
Dehydration
Reduced water intake
Loss of water through the skin (fever, burns, excessive sweating)
Blood loss
Vomiting
Diarrhoea
Renal water loss:
Polyuria (Diabetes Insipidus)
Osmotic diuresis (Diabetes Mellitus)
Malnutrition
Bulimia
Anorexia
2. Changes to the salivary glands
Therapeutic irradiation to the head and neck region
Autoimmune diseases
Sjogren’s syndrome, graft-versus-host-disease, systemic lupus erythematosis
rheumatoid arthritis, etc. HIV-1 infection
Infections
Hepatitis C
HIV
Ageing
Local
Sialadenitis
Sialolithiasis
3. Interference with neural transmission
Medications/drugs
Autonomic dysfunction
Cerebrovascular disease, brain tumors etc.
Conditions affecting the CNS
Alzheimer's disease
Parkinson’s disease
Psychogenic disorders
Depression
Anxiety
Stress
Trauma to the nerves involved in salivary secretion
Decrease in mastication
Adapted from- Sreebny, L.M. & Schwartz, S.S. 1997, "A reference guide to drugs
and dry mouth–2nd edition", Gerodontology, vol. 14, no. 1, pp. 33-47.
 
 
 
 
9According to a review by Orellana et al., (2006), the prevalence of xerostomia, in most
of the studies until then, ranged from 0.9% to 64.8%. This population review once
again highlights the wide range of prevalences for xerostomia that has been reported.
Osterberg et al. (1984) conducted one of the first large-scale studies on the prevalence
of xerostomia. 1148, seventy year old residents from Goteborg, Sweden, partook in it.
In this study 25% of women and 16% of men reported xerostomia. In 1992, Narhi et
al. did a study on 368 subjects and found a prevalence of 46% for xerostomia among
75-85 year olds. The older age group has also shown prevalences as high as 52%
(Putten et. al., 2011). Studies that reflect the population at large include those by
Sreebny and Valdini (1988), Nederfors et al. (1997) and Flink et al. (2008). A
prevalence of 29% was seen in the study by Sreebny and Valdini (1988). 3311
individuals of all ages were included in the study by Nederfors et al. (1997) and it
showed a xerostomic prevalence of 28% for females and 23% for males. In all of the
studies, females were more prone to xerostomic complaints. Flink et al. (2008) have
shown in their study that the prevalence of xerostomia and hyposalivation did not vary
much until the age of 50 years for women and 60 years for men.
Interestingly, xerostomia or dry mouth is rarely a primary complaint among patients.
Being a subjective symptom, like pain, it has to be taken at face value. Diagnosis of
xerostomia can be made either from a positive response to just the single question
“Does your mouth feel dry often?”, (Osterberg et. al., 1984; Flink et al., 2008; Toida
et. al. 2010) or from a response to a multi-item inventory of up to 16 xerostomia
related questions (Narhi, 1994).
Thomson et al. (1999a) made an 11 item inventory that reflects both the individual’s
awareness of xerostomia and actions taken as a consequence of the symptoms. This
inventory is considered as the standard for xerostomia assessment in the Australasian
region. Most authors from the North American region use a set of four questions
developed by Fox et al. in 1987 (Navazesh et. al. 2009; Napeñas et al., 2009; Ship,
2002). In 1988 Sreebny and Valdini selected four questions from their inventory and
found that these questions had a high predictive value and specificity for detection of
reduced salivary flow rate. These four questions have been used in this study to assess
xerostomia. Apart from “yes or no” answers, a graded response of “never”, “hardly
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ever”, “occasionally”, “frequently” or “always” is also used (Thomson et. al., 1999a).
Table-2.3 gives a list of questions used in some of these inventories.
Table 2.3 – Examples of Xerostomia Inventories
Fox PC, Busch KA, Baum BJ. 1987, “Subjective reports of xerostomia and
objective measures of salivary gland performance”, J Am Dent Assoc, Vol. 115,
no.4, pp. 581-584.
1. Does the amount of saliva in your mouth seem too little?
2. Does your mouth feel dry when eating a meal?
3. Do you have difficulty swallowing any food?
4. Do you sip liquids to aid in swallowing dry food?
Response options: Yes/ No
Sreebny L M, Valdini A. Xerostomia. 1988, “Part I: Relationship to other
symptoms and salivary gland hypofunction”, OralSurg OralMed Oral Pathol, vol.
66, no. 4, pp.451-458.
1. Does your mouth usually feel dry?
2. Do you regularly do things to keep your mouth moist?
3. Do you get out of bed at night to drink fluids?
4. Does your mouth usually become dry when you speak?
Response options: Yes/ No
Thomson WM, Chalmers JM, Spencer AJ, Williams SM. 1999, “The
Xerostomia Inventory: a multi-item approach to measuring dry mouth”,
Community Dent Health, vol. 16, no. 1, pp. 12-7.
1. I sip liquids to aid in swallowing food
2. My mouth feels dry when eating a meal
3. I get up at night to drink
4. My mouth feels dry
5. I have difficulty in eating dry foods
6. I suck sweets or cough lollies to relieve dry mouth
7. I have difficulties swallowing certain foods
8. The skin of my face feels dry
9. My eyes feel dry
10. My lips feel dry
11. The inside of my nose feels dry
Response options: Never (scoring 1), Hardly ever (2), Occasionally (3),
Fairly often (4), Very often (5)
 
 
 
 
11
A visual analogue scale, similar to the pain scale, can also be used on a colorimetric
or graduating scale of 1 to 10 (Pai et. al., 2001; Lopez-Verdin et al., 2013). Fig -2.1
shows an example of a visual analogue scale that can be used in evaluating
xerostomia.
Figure 2.1 - Visual Analogue Scale for a xerostomia question.
2.2.2 Hyposalivation
Hyposalivation is a demonstrable reduction in salivary flow rate that can be measured
objectively by collecting saliva over a period of time (Navazesh et al., 1992a;
Navazesh, 1993). While 58% of the xerostomic subjects in one study showed
hyposalivation (Torres et. al., 2002) and 54% in another (Sreebny & Valdini, 1988),
only 22.1% was observed by Thomson et al (1999b). A positive correlation of
xerostomia and reduced salivary flow is not always found.
Some of the causes for reduction in salivary flow include: medication, radiotherapy,
systemic diseases, localised salivary gland disease and dehydration. These causes may
be classified according to the way it affects the salivary glands – damage to gland,
neurotransmission alterations and water loss in the body (Sreebny & Schwartz, 1997).
Table 2.2 gives a list of some of these causes. There are over 400 pharmaceutical
drugs that are implicated in causing xerostomia (Sreebny & Schwartz, 1997).
Evidence of reduced salivary flow is documented for some of them (Navazesh et al.,
1996; Sreebny & Valdini, 1989; Wu and Ship, 1993; Osterberg et. al., 1984; Putten,
2011). Anti-hypertensives, anti-retrovirals, anti-depressants, anti-cholinergics, anti-
psychotics, anti-cancer drugs etc are some of the common culprits. A summarised list
of those medications with the potential to reduce salivary flow is given in Table-2.4.
Never                    Rarely                  Sometimes             Often                    Always
Q - How often do you feel that your mouth is dry?
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Table 2.4 – Medications that have potential to reduce salivary flow rate
Anticholinergic agents
Antiemetics/drugs for vertigo
Anti-parkinsonian drugs
Antispasmolytics:
Gastrointestinal
Mydriatics/cycloplegics
Medications with anticholinergic effects
Antiarrythmics:
Sodium channel antagonists
Antihypertensive agents:
α-adrenergic blockers
β-blockers
calcium antagonists
Antihistamines
Antidepressants
Antipsychotics
Monoamine oxidase inhibitors
Psychotropic agents
Anxiolytic agents:
Benzodiazepines
Medications causing changes in fluid and electrolyte balance
Diuretics:
Thiazides
Loop diuretics
Potassium sparing diuretics
Others
Antineoplastic agents:
Interleukin-2a
Adapted from- Närhi, T.O., Meurman, J.H. & Ainamo, A. 1999, "Xerostomia and
hyposalivation", Drugs & aging, vol. 15, no. 2, pp. 103-116.
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Some drugs, although causing xerostomia, do not actually cause a reduction in salivary
flow (Atkinson et. al., 1989a). The different ways that therapeutic drugs can affect
salivary gland function is through disruption of neural salivatory function,
vasoconstriction within the gland or electrolyte loss affecting salivary gland function
and xerostomic perception. Most of the salivary dysfunction due to medication is
reversible on stopping the drug. There have been a number of studies that show a
negative co-relation between the salivary flow rate and the number of medication and
systemic diseases. (Wu & Ship, 1993; Osterberg et al., 1984; Nederfors et al., 1997).
Radiotherapy as part of treatment for head and neck cancer causes irreversible
destruction of the salivary gland parenchyma. The parotid glands are most sensitive to
ionising radiation, showing up to a 50% decrease in salivary flow within 24 hours of
radiation (Shannon et. al., 1978).
Several systemic conditions can cause salivary dysfunction. The most drastic of these
is Sjogren’s syndrome (SS). SS is an autoimmune disease, mostly seen in women,
involving salivary and lacrimal glands. It is characterised by lymphocyte infiltration of
salivary and lacrimal glands, causing inflammation, accinar destruction and decreased
secretion (Fox, 2005). Xerostomia and hyposalivation are major concerns for sufferers
of this condition. Some of the other systemic conditions associated with salivary gland
dysfunction are HIV/AIDS (Mandel et al., 1992, Yeh et al., 1988), diabetes mellitus
(Sreebny et al., 1992) cystic fibrosis, hepatitis C, sarcoidosis, rheumatoid arthritis,
systemic lupus erythematosus and scleroderma (Von Bultzingslowen et al., 2007).
Compositional changes in the saliva are also seen in systemic conditions like HIV and
diabetes. Hyposalivation is also seen in transplant patients who develop Graft Vs Host
disease (Mandel, 1990).
Dehydration has been known to cause reduced salivary flow (Ship & Fisher, 1997;
Napeñas et al., 2009). Dehydration can be due to reduced water intake, haemorrhage,
vomiting, diarrhoea or renal water loss. Excess alcohol intake and anorexia can also
cause reduced salivary flow. The mechanical action of chewing stimulates salivary
flow. Therefore, where there is reduced mastication, due to loss of teeth, there is
reduced salivary flow (Osterberg et al, 1984). Localised gland diseases like bacterial
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sialadenitis, sialolithiasis and salivary gland tumors and cysts can also cause
hypofunction.
It may be noted at this point, that hyposalivation may be a symptom of a range of
underlying conditions, some of which are physiological, some systemic and more
sinisterly, some pathological. Therefore, when present, diagnosing hyposalivation and
exploring its reasons can be critical not only for the oral health but also for the general
wellbeing of the patient.
An accurate presentation of the prevalence of hyposalivation is difficult since, in some
studies, hyposalivation is described as a flow rate below a certain value (Ericsson &
Hardwick, 1978; Napeñas et al., 2009; Navazesh et al., 2003; Flink et al., 2008;
Osterberg et al., 1984; Sreebny & Valdini, 1988; Navazesh et al., 1992a), and in some
studies, hyposalivation was determined as values below the 10th percentile (Farsi,
2007; Wu & Ship, 1993). Furthermore, different values were used as cut-offs for
abnormal flow rate by different authors. Nevertheless, literature reviews of some of
the studies give a prevalence of 20.2% for hyposalivation (Flink et. al., 2008), in a
study of different age groups and 30-33% (Osterberg et al., 1984), in an older age
group.
Subjective measures of salivary flow rates can be made by collecting
resting/unstimulated saliva and stimulated saliva from the whole mouth or individually
from the different salivary glands (Navazesh, 1993). The saliva is collected in a tube
over a period of time, usually 3 to 5 minutes, and the flow rate is then calculated.
Resting whole mouth saliva is collected by drooling or spitting into a tube fitted with a
funnel. Mechanical (paraffin wax, gum, rubber band), or gustatory (1-10% citric acid
solution, candy), stimulation may be used to collect stimulated saliva. Parotid gland
saliva is collected using a lashley cup or a modified Carlsson-Crittendan device.
Submandibular and sublingual saliva can be isolated and suctioned gently into a tube.
Minor salivary gland secretions can be collected with a micropipette of filter paper and
quantity can be measured using a Periotron (Navazesh, 1993).
Although slight variations exist in the cut-off values for determining abnormal flow
rate, most authors agree on a cut off of ≤ 0.1 ml/min for resting and ≤0.7 ml/min for
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stimulated whole-mouth saliva flow rate. (Navazesh et. al., 2003; Flink et. al., 2008;
Ericsson & Hardwick, 1978; Sreebny & Valdini, 1988)
Clinical signs and symptoms that may help with diagnosing hyposalivation include dry
mucosa (tongue depressor sticks to dry buccal mucosa), dry lip (Navazesh et al.,
1992a; Farsi, 2007), dry fissured tongue, lack of salivary pooling in the floor of the
mouth, increased dental caries (especially cervical and incisal caries) candidial
infection (Torres et. al., 2002; McCarthy et al., 1991), difficulty in denture retention
and enlarged (sometimes tender), salivary glands (Navazesh et al., 1992a). Salivary
flow can also be measured by Scintography. Uptake and secretion of Technicium per
Technatate can be measured to determine accinar function (Napeñas et al., 2009).
2.2.3 Compositional Changes
Salivary compositional changes, due to gland dysfunction, can be observed in the
presence of systemic diseases like pancreatitis, diabetes mellitus (Mandel, 1990),
depression (De Almeida et. al., 2008) and Graft Vs Host disease (Mandel, 1990).
Other conditions include nutritional deficiencies (Humphrey & Williamson, 2001),
increased alcohol consumption (Mandel, 1990), and increased physical exercise (De
Almeida et. al., 2008). Salivary compositional changes in HIV positive patients were
also noted by Mandel et al. (1992), Atkinson et al., (1990), Jainkittivong et al.,(2009)
and Lin et al. (2001 & 2003).
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2.3. HIV AND HAART
In the 33 years since the first case of AIDS was recognized in 1981, HIV infection has
evolved into a condition affecting 34 million people worldwide (Joint UN program on
HIV/AIDS, 2012). Meanwhile, a large amount of resources and manpower has been
poured globally into research bodies towards an increase in knowledge, exploring
treatment modalities and prevention strategies for this pandemic. Infection by HIV is
from transfer through blood, blood products and bodily fluids. Although, initially it
was discovered in the homosexual community, today, most of the transmission
globally is heterosexual. Intravenous drug users and people receiving blood or blood
products are also at risk. Most of the HIV positive children have been infected by
vertical transmission from mother to child.
The average person with HIV infection produces 10 billion virions per day (Ho et. al.,
1995). Anti retroviral treatment (ARVs) is the key to HIV/AIDS management. Before
1987, treatment for HIV/AIDS consisted of the symptomatic treatment of
immunodeficiency complications. Zidovudine (AZT) was the first US govt approved
ART introduced for HIV treatment. Initially it was used in monotherapy and later in a
two drug regimen along with Lamivudine (3TC)
2.3.1 HAART
In the mid 1990s, David Ho and other researchers proposed the idea that a three drug
regimen was the answer to hitting the virus hard and reducing its chance of developing
resistance. This approach was called Highly Active Anti Retroviral Therapy
(HAART). HAART has effectively turned the tide of HIV/AIDS mortalities and made
it a chronic manageable disease rather than a death sentence (ART Cohort
Collaboration, 2008).
There are different types of ARVs and they are mainly classified into 5 groups
depending on their action in the life cycle of the HIV – Nucleoside Reverse
Transcriptase Inhibitor (NRTIs), Non-nucleoside Reverse Transcriptase inhibitors
(NNRTIs), Protease Inhibitors (PIs), Integrase Inhibitors (IIs), and entry or fusion
inhibitors.  Figure-2.2 illustrates the sites in the life cycle of the HIV upon which the
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antiretro-viral drugs may act. Table-2.5 lists the classifications of the various ARVs
that are able to act on the HIV at the different sites of its life cycle.
Figure 2.2- Blocking of HIV replication by ARVs
Taken from: Apostolova, N., Blas-García, A., & Esplugues, J. V. 2011,
“Mitochondrial interference by anti-HIV drugs: mechanisms beyond Pol-γ
inhibition”, Trends in pharmacological sciences, Vol.32, no.12, pp.715-725.
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Table 2.5 - Classification of Anti Retrovirals
Class Site and Mechanism of
Action
Example
NRTI-Nucleoside/
Nucleotide Reverse
Transcriptase Inhibitor
(NtRTI)
When the Viral RNA is
converted to DNA-
Competitive inhibitor of
reverse transcriptase
NRTI- e.g.- Zidovudine
(AZT), Lamivudine
(3TC),Didanosine (ddI),
Stavudine (d4T),
Emtricitabine (FTC), and
Abacavir (ABC)
NtRTI- e.g.- Tenofovir
(TDF)
NNRTI- Non Nucleoside
Reverse Transcriptase
Inhibitor
When the Viral RNA
converts to DNA- Non
competitive inhibitor of
Reverse Transcriptase
Efavirence (EFV),
Nevirapine (NVP)
PI- Protease Inhibitors Prevent cleavage of the
viral proteins
Lopinavir, Ritonavir
(RTV), Indinavir (IDV)
II- Integrase Inhibitors Inhibits the integration of
Viral DNA into the DNA
of the cell
Raltigravir (RAL),
Elvitegravir
Entry Inhibitors or Fusion
Inhibitors
Interfere with binding,
fusion and entry into the
host cell
Maraviroc (MVC),
Enfuvirtide
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HAART regimens usually consist of 3 or more anti retrovirals from at least 2 different
classes ensuring antiviral action at different stages of HIV replication. HAART
regimens may consist of any of the combinations below:
 2 NRTIs + 1 NNRT
 2 NRTIs + 1 PI
 2 NRTIs + 2 PIs
 2 NRTIs + 1 II.
In South Africa the HAART regimens currently in use are 2 NRTIs + 1 NNRTI for
first line of treatment and 2 NRTIs + 1 PI for second line of treatment. In April 2013,
the National Department of Health launched a Fixed Drug Combination (FDC), to be
initiated in the newly diagnosed and rolled out in phases to the different groups
according to priority. It is a single pill containing Efavirenz, Tenofovir and
Emtricitabine (2 NRTIs + 1 NNRTI) (Nat Dept of Health, 2013).
2.3.2 Oral manifestations of HIV in the HAART era
Since the early days of its emergence, HIV has been associated with a variety of oral
lesions. A good comparison of the studies on oral manifestations in HIV was done by
Patton et al. in 2002 and more recently, in 2013. The pre HAART prevalence for oral
manifestations was 92% (Klein et. al., 1991), 82% (Nittayananta & Chungpanich,
1997) and 60% (Arendorf et. al., 1998). A clear decline in oral manifestations was
seen with the advent of HAART (Greenspan et. al., 2004; Schmidt-Westhausen et. al.,
2000; Ortega et. al., 2009; Masiiwa & Naidoo, 2011). The most significant change was
seen in the reduction of oral candidiasis, oral hairy leukoplakia and Kaposi’s sarcoma
(Greenspan et. al., 2004; Nittayananta et. al., 2010a; Schmidt-Westhausen et. al., 2000;
Hamza et. al., 2006; Ortega et. al., 2009). Apart from improving immune status, PIs
have been shown to reduce candidial infection. This could possibly be due to the direct
protease inhibitory action by the PIs on the candidial aspartyle proteases (Cassone et
al., 2002; Munro & Hube, 2002). In Zimbabwe, Masiiwa & Naidoo (2011) conducted
a prospective study to determine the prevalence of oral lesions before and after
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HAART. Manifestations of oral lesions reduced from 86% at baseline to 57% in 6
months. Although a decrease in most oral lesions is seen with HAART initiation, an
increase in prevalence was noted for some other lesions like oral pigmentation
(Umadevi et. al., 2007), oral warts (Masiiwa & Naidoo, 2011; Patton et. al., 2000;
Greenspan et. al., 2001), and HIV associated salivary gland disease (HIV-SGD)
(Greenspan et. al., 2001; Patton et. al., 2000; Naidoo & Chikte, 2004; Matee et. al.,
2000).
Oral manifestations are commonly useful in indicating HIV infection, predicting
immune status and in staging and classification of the disease (Coogan et. al., 2005).
In the HAART era, oral manifestations can still be useful as indicators of reduced
immunity due to treatment failure from non-adherence or development of drug
resistance (Greenspan & Greenspan, 2002). Distinctions should still be made between
manifestations of the disease, of adverse drug reaction and of immune reconstitution
inflammatory syndrome (IRIS).
2.3.3 Orofacial Side Effects of HAART
As the number of people on HAART increases, and the drugs used in therapy become
more complex, the incidences of undesirable or adverse effects will only increase.
They may vary from mild oral pigmentations to a serious systemic reaction like
erythema multiforme (Dios & Scully, 2014). Reports of clinical symptoms and
laboratory adverse effects can be up to 78% (Fellay et. al., 2001), during HAART.
With NRTIs, especially Zidovudine, bone marrow suppression may be observed. This
can manifest as oral ulcerations secondary to neutropenia (Dios & Scully, 2013). Other
oral side effects include xerostomia, erythema multiforme and lichenoid reactions
(Dios & Scully, 2014). Abnormal liver functions may be seen with Lamivudine and
Stavudine. Hyperpigmentation is listed as a side effect for Emtricitabine. Xerostomia
is associated with didanosine (Allan et. al., 1993), Emtricitabine and Lamivudine
(Dios & Scully, 2014). Facial lipoatrophy is seen in treatment with Stavudine and
Tenofovir. NNRTIs generally are tolerated well and have less oral side effects.
Erythema Multiforme and ulcers are the most common expression of hypersensitivity
 
 
 
 
21
on treatment with NNRTIs (Dios & Scully, 2014). PIs have been associated with
parotid lipomatosis (Olive et. al., 1998; Ceballos-Salobrena et al., 2000), xerostomia,
reduced salivary flow (Navazesh et. al., 2003), taste disturbances (Murri et. al., 2000)
and circumoral parasthesia (Porter & Scully, 1998). The exact mechanism of ARVs
causing reduced salivary flow is unknown. It may be a result of the direct action of the
drug leading to accinar changes or lipotrophic tissue changes within the gland causing
an anti secretory effect (Navazesh et al., 2003; Olive et al., 1998). A concise list of the
orofacial effects of the various classes of ARVs can be seen in table- 2.6
Table 2.6 – Orofacial adverse effects of ARVs
Drug Possible Orofacial adverse effects
Abacavir (ABC) Erythema multiforme
Didanosine (DDI) Dry mouth
Facial lipoatrophy
Erythema multiforme
Emtricitabine (FTC) Hyperpigmentation
Dry mouth
Lamivudine (3TC) Dry mouth
Stavudine (D4T) Facial lipoatrophy
Tenofovir disoproxil (TDF) Facial lipoatrophy,
Zidovudine(azidothymidin, AZT, ZDV) Erythema multiforme
Hyperpigmentation
Lichenoid lesions
Facial lipoatrophy
Ulcers
Efavirenz (EFV) Erythema multiforme
Swelling
Burning mouth
Clefts
Nevirapine (NVP) Erythema multiforme
Swelling
Ulcers
Taste disturbance
Lichenoid lesions
Dry mouth
Burning mouth
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Indinavir (IDV) Cheilitis
Parotid lipomatosis
Dry mouth
Taste disturbance
Ritonavir (RTV) Perioral paraesthesia
Parotid lipomatosis
Dry mouth
Taste disturbance
Swelling
Adapted from- Diz Dios, P. & Scully, C. 2014, "Antiretroviral therapy: effects on
orofacial health and health care", Oral diseases, vol. 20, no. 2, pp. 136-145.
2.3.4 Immune Reconstitution Inflammatory Syndrome (IRIS)
IRIS is the worsening of a pre-existing condition or an unmasking of an occult
infection in an immunocompromised patient on HAART. It is not due to drug toxicity
and occurs within weeks or a few months of treatment initiation. This is seen in
conjunction with a quantitative increase in CD4 count and a decrease in viral load
(Zolopa et al., 2009). Disease relapse, drug resistance and non-compliance have to be
excluded before making this diagnosis (Shelburne et. al., 2006). Approximately 25%-
32% of all patients on HAART develop IRIS (Feller et. al., 2007).  Ramirez-Amador
et al. (2009) suggested an inclusion of oral candidiasis, oral hairy leukoplakia and
recurrent oral ulcers as possible manifestations of IRIS. Feller et al. (2007, 2008)
reported Herpes Zoster and Kaposi’s sarcoma as possible oral manifestations of IRIS.
HPV associated oral lesions that were seen to be on the increase in patients on
HAART could also be a part of IRIS (Greenspan et. al., 2001; Patton et. al., 2000;
Flint et. al., 2006)
A retrospective study by Ortega et al. (2009) reported salivary gland enlargement as
the most common oral manifestation in a group presenting with IRIS. An increase in
salivary gland disease in patients on HAART was also seen by Greenspan et al.
(2001). This could be due to infiltration of the salivary gland by CD8 lymphocytes as
part of Diffuse Infiltrative Lymphocytosis Syndrome (DILS). IRIS may be a
manifestation of a recovering immune system that is functionally incomplete and so its
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effectiveness may vary in response to the presence of different pathogens and antigens
(Greenspan et. al., 2001).  
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2.4. HIV ASSOCIATED SALIVARY GLAND DISEASE (HIV-SGD)
In 1989, Schiodt et al. (1989) first used the term HIV associated Salivary Gland
Disease (HIV-SGD) to describe a group of salivary gland disorders that affected the
HIV positive population. Non-neoplastic changes like Benign Lymphoepithelial Cysts
(BLEC), diffuse infiltration of salivary glands by CD8 lymphocytes, Sjogren’s
syndrome-like condition and Sicca complex were all seen in HIV positive patients.
How much of it was overlap, was not clear. Hence, he coined the term HIV-SGD to
designate “Xerostomia, enlargement of one or more of the major salivary glands, or
both” (Schiodt et al., 1989).  This was essentially what was clinically observed in the
above conditions – salivary gland enlargement and/or xerostomia in the HIV positive
individuals. Since then, compositional changes in the saliva by HIV infection have
also been reported (Mandel et. al., 1992; Atkinson et. al., 1990; Lin et. al., 2001, 2003,
2004; Jainkittivong et al., 2009; Johar et. al., 2011).
HIV-SGD is often pathognomic of HIV in the paediatric population and is not
observed as much in the adult population. Naidoo and Chikte (2004) reported a
prevalence of 50% for Parotid gland enlargement in 71 institutionalised HIV +
children in South Africa. None of them were on Anti Retroviral Treatment. In 2012,
Sales-Peres et al. observed 23% Parotid Gland Enlargement (PGE), and 76%
hyposalivation among HIV/AIDS patients in a paediatric hospital in Mozambique.
Some of these children were on ART. In a Tanzanian study, Hamza et al. (2006),
reported PGE in 18.2% of the children who were pre-HAART and this rose to 20% in
those who were on HAART. They also remarked on the lack of significant decrease in
other oral manifestations among children who were on HAART.
In the same study, Hamza et al. (2006) also reported 2.2% prevalence for PGE among
the adult population who were not on HAART and this rose to 4.9% among those who
were on HAART. Although there was a significant decline in many of the other oral
manifestations, the sharp increase in PGE could be attributed to IRIS. In their study,
Ceballos-Salobrena et al. (2000) noted a prevalence of 15.5% for xerostomia and 4.5%
for PGE among the HIV positive subjects. All of the study subjects were being treated
with HAART which included PIs. It does, however, remain unclear whether the PGE
and xerostomia could be attributed to HIV infection, HAART or a combination
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thereof. As mentioned earlier, many ARVs are implicated in causing xerostomia and
reduced salivary flow, especially the PIs. PGE due to lipomatous changes have also
been observed during treatment with PIs (Olive et. al., 1998; Ceballos-Salobrena et al.,
2000)
Among the adult population, HIV-SGD does not seem to be limited to any particular
risk group in terms of mode of transmission and can occur in any stage of the disease
(Schiødt et al., 1992). HIV-SGD is prominently associated with DILS (Diffuse
Infiltrative Lymphocytosis Syndrome) where CD8 lymphocytic infiltration is seen in
other organs as well. According to Itescu et al. (1990), DILS appears to have a
predilection to the male black population. McArthur et al. (2000) has estimated the
prevalence of DILS in a Cameroonian study of AIDS patients to be 48%. Although,
according to Itescu et al. (1993), and Rivera et al. (2003), DILS appears to have a
predilection to the male population, a recent study by Kungoane (2010) showed that
lymphoid proliferation among children had an almost equal gender distribution.
The exact mechanism of salivary gland dysfunction due to HIV infection is not clearly
understood. While some investigators like Greenberg et al. (1997) have suggested a
strong relationship between xerostomia and a co-infection with the Cytomegalovirus
in HIV patients, most are agreeable on lymphocytic infiltrate of the glandular tissue as
the reason for HIV-SGD (Schiodt et al., 1992).
2.4.1 Pathophysiology
During embryonic development, a few (5-10) lymph nodes are trapped in the Parotid
gland tissue, and trapped within these lymph nodes, are pieces of salivary gland tissue.
During the course of HIV infection, due to viral replication, there is an initial host
response to lymphoid proliferation. This is characterised by the generalised
lymphadenopathy seen in the disease. The lymphoproliferative activity within the
intraglandular lymph nodes or by the lymphocytes normally present in the gland can
cause gland enlargement (Mandel & Reich, 1992).
In the early stages, glandular tissue and lymph nodes show varying degrees of
progressive CD8 lymphocyte infiltration, which can later lead to cystic changes
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(Mandel et. al., 1998; Itescu et. al., 1990, 1993). Initially, cystic formation was thought
to be due to the lymphoid proliferation causing ductal obstruction (Ioachim & Ryan,
1988). Microscopic studies have shown epithelial cells lining the cyst (Elliott &
Oertal, 1990). These are thought to be derived from gland accini and ductal tissue that
were trapped within the intraglandular lymph node during embryogenesis. Thus, a
proliferation of this tissue within the lymph nodes is implicated in the formation of
cysts filled with keratinaceous and proteinaceous debris (Mandel et. al., 1998).
Due to the differences during embryonic development, the lymph nodes associated
with the submandibular gland stay extra glandular and hence the lymphadenopathies
associated with these glands are extra glandular (Ioachim & Ryan, 1988; Mandel &
Reich, 1992). Histologically, apart from diffuse CD8 lymphocyte infiltrates, the
parenchymal tissues also show degeneration (Schiødt et. al., 1992). Periductal
lymphocytic infiltration, accinar atrophy and ductal ectasia with varying amounts of
fibrosis were noted by Rivera et al. (2003).
Itescu et al. (1990) reported a decrease in the CD4/CD8 ratio in patients with HIV
related parotid gland enlargement (PGE) and stated that they have a more favourable
progress. Katz et al. (1993) has also indicated that the presence of salivary gland
enlargement is associated with a slower progression to death. This may be due to the
protective effect of the increased CD8 T-Cells that are seen in these conditions.
Salivary gland enlargement due to lymphocytic infiltration is a hallmark of DILS
(Itescu et al., 1990); seen in some HIV positive patients and not in others. It could also
mark a favourable ability by this subset of the HIV infected population to mount a
defensive response to the HI Virus (Itescu et al., 1990; Jeffers & Webster-Cyriaque,
2011).
DILS is characterised by swelling of the salivary and lacrimal glands. There is an
increased CD8 lymphocyte infiltration of these glands and the kidney, nerves,
muscles, lungs, gastric mucosa and lymph nodes (Itescu et al., 1990; Rivera et al.,
2003). DILS of the salivary gland mimics Sjogren’s syndrome and so it is sometimes
referred to as an SS-like condition. Although the clinical signs and symptoms are
similar, the differences are unmistakable. While in DILS and related HIV-SGD, the
lymphocyte infiltrate is predominantly CD8, in SS, there is an increase in the CD4
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lymphocyte within the glandular tissues. There is also a lack of autoimmune
antibodies in DILS (Itescu et al., 1990; Rivera et al., 2003). SS is almost always seen
in women, but in reports of DILS, there seems to be a male predilection (Rivera et al.,
2003). Viral etiologies have been proposed for both (Jeffers & Webster-Cyriaque,
2011).
According to Itescu et al. (1990), the CD8 infiltration appears to be a genetically
determined (major histocompatibility) host immune response in the presence of HLA-
DR5; possibly, to a viral antigen (Itescu et al.,1993; Mandel et al.,1998). Many
virological etiologies have been investigated for HIV-SGD. HIV (Mandel et al., 1998;
Rivera et al., 2003; Itescu, 1990), Cytomegalovirus (CMV) (Greenberg, 1997), Epstein
Barr Virus (EBV) (Rivera et al., 2003), and recently the BK Virus (Jeffers & Webster-
Cyriaque, 2011; Burger-Claredon, 2014), have all been proposed as causative
pathogens. Over time, CMV has been out ruled by some investigators (Rivera et al.,
2003; McArthur, 2000). The presence of the EBV antigen and HIV1-p24 antigen
within the ductal epithelial cells has been demonstrated by Rivera et al. (2003). Lack
of significant evidence to imply EBV as a cause has ruled it out (Chetty et. al., 1999).
In 2009, Jeffers et al. were able to demonstrate tropism by BKV, a polyoma virus, for
salivary gland cells. They detected BKV in the saliva of patients with HIV-SGD and
proposed an oral route of transmission. Symptoms of BKV in generally healthy people
are subclinical; followed by viral dissemination to sites like urinary tracts and kidney
for life-long persistence (Jeffers & Webster- Cyriaque 2011). Like most opportunistic
pathogens, clinical manifestation occurs during immunosuppression. Since HIV-SGD
is seen to be more prevalent in children than adults, Jeffers & Webster Cyriaque
(2011) postulated that “this may indicate primary viral infection Vs residual immunity
in adults”.  Currently, a clinical trial has been undertaken by the University of North
Carolina to learn more about the role of BK virus in Salivary gland diseases and to
determine its relationship to HIV-SGD (Webster-Cyriaque, 2014).
Apart from the parotid glands, HIV-SGD also affects the submandibular, sublingual
glands and minor salivary glands (Mc Arthur et al., 2000; Schiodt et al., 1989).
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2.4.2 Clinical Presentations
Clinically, HIV-SGD can present as any of the following in an HIV positive patient.
 Enlargement
 Symptoms of Xerostomia
 Changes in salivary flow rate
 Changes in salivary composition.
The above may be present alone or along with the other signs and symptoms. Salivary
gland enlargement is more readily noted in the parotid than in the submandibular or
sublingual glands. Parotid gland enlargement is more prevalent in children (50%) than
in adults (2.2%), (Naidoo & Chikte, 2004; Hamza et al., 2006). PGE in children is an
important clinical sign as it has been linked to favourable prognosis (Katz et al., 1993;
Itescu et al. 1990). The swelling may be firm mostly non-tender on palpation.
Sometimes fluctuant swellings can be found depending on the size and stage of cystic
formation. On initiation of ARVs in a treatment-naive individual, there is a regression
of the enlargement in most of the patients (Mandel et al., 1998, Schiødt et al., 1992;
Kungoane, 2010)
Xerostomia and reduced salivary flow have been associated with HIV since its early
stages of discovery (Yeh et al., 1988; Mandel et al., 1992). In a longitudinal study
Atkinson et al. (1989b) have observed that in HIV positive individuals, the function of
the submandibular gland is affected earlier in the disease and the parotid is affected
later. Navazesh et al.(2000,2003), in a longitudinal studies of a large cohort of HIV+
and “at risk” women, have associated being HIV positive , low CD4 counts , high viral
loads and HAART to reduced salivary flows and increased xerostomic complaints.
Lopez-Verdin et al. (2013) could not associate a low CD4 or increased viral load to an
increase in xerostomia or to a reduction in salivary flow rate. Schiødt et al., (1992)
proposed that the reduction in salivary flow is “likely to be a function of the degree of
inflammatory infiltrate in the gland but not associated with degree of immune
deficiency”. Nittayananta & Chungpanich (1997) reported a prevalence of 63% for
xerostomia among a group of Thai people with AIDS. Australian and Brazilian studies
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by Jeganathan et al., (2012) and Busato et al., (2013) have reported 38% & 40%
xerostomia respectively among HIV positive people.
Reduced salivary flow in HIV positive patients has been documented in so many
studies that its association to the disease is globally accepted (Yeh et al., 1988; Mandel
et al., 1992; Navazesh et al., 2000, 2003, 2009; Nittayananta 2010a). Lopez-Verdin
(2013) has reported taste disturbances in those patients that are not on ARVs; ruling
out a drug side-effect as a reason. Salivary compositional changes are also present due
to HIV infection. An increase in the concentration of lactoferrins, lysozymes, IgA,
histatins, chlorides, sodium, mucins and peroxidases was observed (Mandel et al.,
1992; Fox, 1992; Atkinson et al., 1990, Yeh et al., 1988; Jainkittivong et al., 2009; Lin
et al., 2001 & 2003). Although there is an increase in the concentration of many
protective components, due to the reduction in salivary flow rate, the secretory rate of
these in the saliva is reduced, thereby, reducing the antimicrobial, antifungal and
antioxidant properties in saliva (Lin et al., 2003). Lin et al. (2001) also reported an
increase in candidial carriage in the saliva of HIV positive subjects. These
compositional changes along with reduced salivary flow, which in itself is a risk for
candidial infection (Torres et al., 2002), would account for the increased prevalence of
oral fungal infections in these immune-compromised individuals.
2.4.3 Effect of HAART on HIV Associated Salivary Gland Disease
Xerostomia and Parotid Gland Enlargement have often been associated with HAART
(Ceballos-Salobrena et al., 2000; Greenspan et al., 2001; Lopez-Verdin et al., 2013;
Navazesh et al., 2003). In a longitudinal cohort study of 1000 HIV positive subjects
by Ramirez-Amador et al. (2003), xerostomia was found to decrease in prevalence as
they progressed from being treatment- naive to monotherapy to HAART. HIV-SGD
(possibly indicating PGE) did not show a significant reduction.
In 2010, two Thai studies were published by Nittayananta et al. (2010a & 2010b); one
on the oral health status of HIV+ individuals before the HAART era and the other on
the long term effects of HAART.  HIV positivity was a significant factor in increased
xerostomia and reduced salivary flow. Long term (> 3 yrs) HAART was more
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associated with increased hyposalivation than short term (<3 yrs) HAART.
Xerostomia appears to reduce with HAART initiation but slowly increases with
increased duration of HAART. Navazesh et al., (2003) and Lopez-Verdin et al. (2013)
also reported reduced salivary flow, with increasing number of years on HAART.
Navazesh et al. (2009) and Silverberg et al. (2004) have reported from a large cohort
study of HIV positive women that the occurrence of xerostomia and reduced salivary
flow is least in the “stable HAART” group, higher in “HAART naive” participants and
was highest among those who switched or discontinued HAART.
Most of the earlier studies on the effect of HAART on salivary glands were of
HAART with Protease Inhibitor-regimens. Recently, Johar et al. (2011), and Pavithra
et al. (2013), have shown no change and even a slight increase in salivary flow rates in
those undergoing HAART. In the latter study, all the patients were on 2 NRTIs + 1
NNRTI. Individuals on HAART appear to show improvement in the taste disturbances
associated with some HIV patients (Lopez-Verdin et. al., 2013). In their study, Lin et
al. (2006) reported that although there is a marked increase in candidial carriage in the
saliva of HIV positive subjects, there is a slight reduction in candidial carriage among
those on HAART; also noted by Navazesh et al. (2005). Uric acid, which is an
antioxidant, appears to be greater in concentration in the HAART group when
compared to those not on HAART (Lin et. al., 2006).
Saliva contains secretary leukocyte protease inhibitors (SLPI) that have an anti-HIV
activity accounting for its low infectivity through saliva (Lin et. al., 2004). Lin et al.
(2004) reported that although the secretary rate of SLPI is reduced in HIV, there is a
slight increase in the rate of SLPI under HAART. This further reduces the chance of
salivary transmission of HIV from those under treatment.
Although the rate of secretion of many salivary components is reduced in HIV positive
individuals, HAART does not appear to make it worse (Lin et. al., 2006; Jainkittivong
et al., 2009).
Navazesh et al. (2005) have shown in their study that HAART is a significantly
independent risk factor in the increased occurrence of various bacterial pathogens in
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the saliva of HIV positive subjects, suggesting that “HAART promotes an increasing
pathogenic salivary microbiota, at least temporarily”.
Since the symptoms of salivary gland dysfunction are similar, it is difficult to discern
how much of it is the course of the disease, how much is due to adverse effects from
HAART usage and how much is part of IRIS due to host response from a recovering
immune system when under treatment.
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2.5. IMPACT OF SALIVARY GLAND DISEASE
The old adage that “You don’t miss something until it is gone”, is true in the case of
saliva. Normal salivary function, and the impact that it has on our quality of our life is
mostly taken for granted until there is salivary gland dysfunction. As discussed earlier,
the prevalence of xerostomia and hyposalivation in the general population varies but is
more among the aged population. With the increasing spread of diseases like HIV and
Hepatitis C, salivary gland dysfunction is going to be encountered more and more by
the clinician.
Although a consistent relationship between xerostomia and reduced salivary flow has
often been hard to establish, Rostron et al. (2002), have reported decreased health
related quality of life (QOL), in xerostomic patients who did not show any reduction
in salivary flow. Busato et al. (2013), and Jeganathan et al. (2012), have also reported
on reduced QOL in HIV patients who complain of xerostomia. Xerostomia has also
been associated with other oral sensory complaints like burning mouth and taste
alteration (Lopez-Verdin et al., 2013).
In patients with reduced salivary flow, the saliva is often thick, stringy or of a foamy
consistency. The oral mucosa loses its healthy glisten and can become dry and is more
prone to trauma and infection (Atkinson & Fox, 1992; Torres et. al., 2002). The
tongue may appear dry, cracked or fissured with loss of papillae (Navazesh et al.,
1992a; Sreebny & Schwartz, 1997).
Recurrent candidial infections (Torres et. al., 2002; Mandel et al., 1992; Navazesh et.
al., 2003), gingivitis and angular cheilitis are also a common suffering. These
individuals often have problems with chewing, swallowing, tasting and speaking
(Cassolato & Turnbull, 2003). Difficulties in speech and mastication can cause some
people to avoid social engagements. Some people who suffer from chronic xerostomia
may be at an increased risk of depression (Stevenson et. al., 2004). Due to difficulty
encountered in eating foods that are dry, spicy or acidic, dietary habits are often
changed. Oral health status influences food choices, and thus, the intake of key
nutrients (Rhodus, 1988).
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Patients who have “Dry mouth” often experience sleep disturbances due to the need to
quench their thirst (Cassolato & Turnbull, 2003). Generally, salivary flow is lowest
during the night (Dawes, 1972), and the discomfort is worsened in the presence of
salivary gland dysfunction. This is compounded further in mouth breathers (Narhi,
1994). Denture wearers often have trouble with denture retention and recurrent
candidial infections. Reduced salivary flow impairs salivary defence mechanisms (Lin
et al. 2003), and reduces lavarge, pH and buffering action. All this makes these
individuals prone to dental caries, especially at non-susceptible sites like cervical and
incisal margins (Percival et. al., 1994; Sales-Perez et. al., 2012). Children who are HIV
positive should be considered as high risk for caries due to reduced salivary flow and
intake of chronic syrupy medication (Naidoo & Chikte, 2004). Navazesh et al., (2010)
have associated low salivary flow to increased HIV-1 shedding in saliva, increasing
the risk of salivary transmission. Facial asymmetry and disfiguration caused by
varying degrees of PGE is also a cause for concern among patients affected by HIV-
SGD.
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2.6. TREATMENT OPTIONS
A good medical history and thorough oral examination is essential before making a
diagnosis of salivary gland dysfunction. A step by step management (Table – 2.7)
should include:
1. Alleviating symptoms
2. Treatment of oral conditions
3. Taking preventive measures
4. Improving salivary gland function
5. Managing underlying conditions
Table 2.7- Treatment of Xerostomia, Hyposalivation & Related Oral Complications
Management of
symptoms
Diet and habit modifications
Frequent and regular sips of water
Avoidance of dry, hard, sticky, acidic foods
Avoidance of excess caffeine and alcohol
Salivary substitutes and lubricants
Artificial saliva, Rinses, Gels, Sprays,
Toothpastes
Use of bedside humidifier during sleeping hours
Preventive measures Increased frequency of oral/dental evaluation
Topical fluoride application, Varnish (0.5% NaF)
Daily use of fluoridated dentifrice, Topical: over-the-counter
(0.05% NaF); prescription (1.0% NaF, 0.4% SnF)
Treatment of oral
conditions
Dental caries
Restorative therapy, topical fluoride
Oral candidiasis
Chlorhexidine (CHX) 0.12%:  rinse, swish, and spit 10
ml twice daily
Nystatin/triamcinolone ointment for angular cheilitis:
apply topically 4 times daily
Clotrimazole troches: 10 mg dissolved orally 4–5
times daily for 10 days
Systemic therapy for immunocompromised patients
Denture antifungal treatment: soaking of denture for
30 min daily in CHX or 1% sodium hypochlorite
Bacterial infections
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Systemic antibiotics for 7–10 days
Ill or poor fitting prostheses
Denture adjustment; Hard and soft reline;
Use of denture adhesives; Implant-borne prostheses
Increase salivary
flow
Sugar-free, xylitol-containing mints, candies, and gum
Sialogogues: Pilocarpine: 5–10 mg orally 3 times daily
Cevimeline: 30 mg orally 3 times daily
Acupuncture
Manage underlying
systemic conditions
Multidisciplinary management with other health-care
providers.
Adapted from- Napeñas, J.J., Brennan, M.T. & Fox, P.C. 2009, "Diagnosis and
treatment of xerostomia (dry mouth)", Odontology, vol. 97, no. 2, pp. 76-83.
2.6.1 Alleviating symptoms
The discomfort of having a dry mouth can be alleviated to some extent by using
salivary substitutes and lubricants that can provide mucosal wetting. Artificial saliva
solutions, rinses, gels and sprays are available. Most of them contain
carboxymethylcellulose or mucins or mucopolysaccharides; alone or in various
combinations. In addition, sipping water/fluids throughout the day can help. Dietary
adjustments can be recommended to avoid foods that cause irritation or that are
difficult to chew or swallow. A balanced diet should be planned so that nutritional
elements are not missed out. Consuming food accompanied by frequent sips of water
can help. Avoidance of excess caffeine, alcohol and smoking can be advised. The use
of an indoor humidifier, especially at night, can alleviate some of the discomfort from
dry mouth, dry eye, dry nose and dry skin.
2.6.2 Treatment of oral conditions
Dental caries is a major problem in patients with reduced salivary flow. Apart from
removal of caries and restoration of teeth, the clinician must ensure that the margins of
restorations are accessible for cleaning and integrity checks. Fluoride-releasing
materials like glass ionomers and compomers are the materials of choice. Oral thrush,
angular cheilitis and gingivitis can be treated with antifungals and antibiotics. In the
immunocompromised patient, systemic antifungals may be needed, depending on
immune capacity. Topically, Nystatin cream, amphotericin B lozenges may be used.
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Dentures should be treated by soaking in chlohexidine or 1% Sodium hypochlorite
solution. Antifungal cream can also be used on the denture. Chlorhexidine mouth wash
can be used twice a day to treat gingival inflammations and ulcers. Use of
triamcinolone based ointments for oral ulcers are useful.
In the case of Parotid gland enlargement (PGE), due to lymphocyte infiltrate, initiation
of ART usually shows regression (Schiodt et. al., 1992; Hamza et. al., 2006; Mandel &
Surattanont, 2002). Sometimes, swellings arise as part of IRIS while on HAART.
These eventually regress. Syebele & Butow (2011) reported a 100% reduction in PGE
due to Benign Lymphoepithelial Cysts (BLEC) with the initiation of HAART. No
IRIS was reported in this study of 10 patients. Surgical treatment to restore facial
symmetry has been recommended by some authors (Schiodt et. al., 1992). Due to the
close association of the facial nerve to the parotid gland, nerve palsy is of concern
during parotidectomy procedures.
Repeated fine-needle aspiration (FNA) has shown good results (Jacob et al., 2013).
FNA is also useful for confirmation of cysts and ruling out malignant changes.
Lymphoepithelial cysts have been known to develop non-Hodgkin’s Lymphomas (B-
cell type), making it a pre malignant lesion (Itescu et. al., 1992; Mandel et. al., 1998;
Rivera et al., 2003). Hence, long-term monitoring is necessary. Low-dose radiotherapy
has been used successfully by some researchers (Beitler et al., 1995). Due to the long
term consequences, radiotherapy in benign lesions is to be questioned. Sclerotherapy
by intraoral injection of BLEC with doxycycline or alcohol has also been done (Jacob
et. al., 2013).
2.6.3 Taking preventive measures
Frequent oral examination is mandatory, especially until caries control is achieved. In-
office application of acidulated phosphofluoride (APF) gel in a tray, 4 times a year, is
recommended. Meticulous oral hygiene and a low sugar diet are advised. Neutral PH
fluoride daily rinses should be part of routine oral hygiene. Use of alcohol-based
mouth washes should be avoided as they can further dry out the mucosa. Increased use
of topical and or systemic fluorides can increase fluoride levels in the saliva to
therapeutic levels (Duckworth et al, 1987). This can assist in remineralisation of
enamel.
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If radiotherapy is planned for lymphoepithelial cysts or tumors, a pre-radiation oral
treatment plan should include removal or minimising of all potential risks for dental
abscess. A discussion with the radiologist can be made on the possibility of sparing
one or more salivary glands. Radiation protection stents can be fabricated to protect
the glands of the ipsilateral side. Surgical transfer of submandibular glands, to outside
the radiation field, before radiotherapy, is an option being recommended (Jha et al.,
2003).
2.6.4 Improving salivary gland function
Mastication is a strong stimulant for salivation and it also has a long term beneficial
effect on salivary secretions. Jenkins & Edgar (1989) showed that chewing sugar-free
gum 4 times daily for 8 weeks increased unstimulated whole saliva. Research by
Steinberg et al. (1992) has shown that using gum with xylitol or sorbitol improves oral
health by reducing plaque accumulation, gingival inflammation and assists in enamel
remineralisation.
Drug therapy with Pilocarpine and Cevimeline, in patients with enough functioning
exocrine tissue and in whom it is not medically contra-indicated, has shown
appreciable increase in salivary flow. Pilocarpine taken orally as 5 mg, 4 times daily,
half an hour before a meal, and at bedtime has been recommended (Napeñas et
al.,2009 ; Ship, 2002). Cevimeline is taken as 30mg tablets orally, 3 times daily. Side
effects of these drugs include: increased perspiration and increased bowel and bladder
activity (Von Bultzingslowen et. al., 2007).
Some acupuncture techniques have also been shown to increase salivary flow
(Napeñas et al., 2009).
2.6.5 Managing underlying conditions
If the salivary gland hypofunction is due to medication, the possibility of changing the
type of medication to one with lesser anti-cholinergic effects or changing the time of
administration can be discussed with the physician. In the case of hyposalivation
caused due to the effect of HAART, changing the drug regimen is not always a
feasible option. Fortunately, the PI based regimen, which has been the one repeatedly
implicated in salivary gland hypofunction, is no longer included in the first- line
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treatment of newly diagnosed HIV positive patients (Nat Dept of Health, 2013). In the
current guidelines, the PI based regimen is reserved for those patients failing on the
first line of treatment, thereby, reducing the number of total patients on protease
inhibitors currently. In these patients, when they have been diagnosed with xerostomia
or hyposalivation, other preventive, therapeutic and supportive measures, mentioned
previously, may be used.
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2.7 CONCLUSION
In summary, the presence of salivary gland sub-function in some HIV positive
patients, is determined in part by the effect of the viral antigens and leukocytic
infiltration present in the glandular tissue, in part by the CD4 count and extent of
immune suppression and in part by the effect of HAART directly or indirectly by an
inflammatory response from a recouping immune system.
Despite the cause, diagnosis of xerostomia and hyposalivation and its alleviation
should play an important part in the overall management of the HIV positive patient.
Knowledge about the prevalence, co-relations and possible confounders of xerostomia
and hyposalivation is the first step in making the clinician aware of the need for
exploring the presence of these conditions while managing the oral health of HIV
positive patients. This study aims to contribute towards this.
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CHAPTER_- 3
RESEARCH DESIGN AND METHODOLOGY
3.1 AIM
To compare the prevalence of xerostomia and hyposalivation, in HIV positive patients
on HAART, HIV positive patients not on HAART and HIV negative patients,
attending Empilweni Gompo community health centre (EGCHC) in East London.
3.2 OBJECTIVES
1. To determine the prevalence of Xerostomia, using a questionnaire, in HIV
positive patients on established HAART, in HIV patients not on HAART and
in a HIV negative group.
2. To determine the prevalence of hyposalivation by measuring whole mouth
salivary flow rates (resting and stimulated) in the above mentioned three
groups.
3. To compare xerostomia responses and salivary flow rates across the 3 groups.
4. To co-relate reduced salivary flow with low CD4 counts in the HIV positive
groups.
3.3 NULL HYPOTHESIS
“There is no difference in the prevalence of xerostomia and hyposalivation in HIV
positive patients on HAART, HIV positive patients not on HAART and HIV negative
patients”
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3.4 METHODOLOGY
3.4.1 Study design
The study design was a cross sectional analytical study.
3.4.2 Site
The study was conducted at the Empilweni Gompo Community Health Centre, a
primary health care facilities in the city of East London, Eastern Cape. East London is
situated in the Eastern Cape. It has a population of about 267,000 people. Empilweni
Gompo CHC is one of the two community health care centres in East London and falls
under the Buffalo City Health district. It has a catchment population of about 57,900
from the surrounding areas.
About 12,000 patients are seen at the centre on a monthly basis as outpatients. There
are about 1300 patients currently on the ARV programme here.
.
3.4.3 Sample/Population
Patients attending the HIV Counselling and Testing centre (HCT) and the ARV clinic
at EGCHC in East London city of age group- 18 to 55 years were invited to partake in
the study. Willing patients were included in the study on a daily basis until the set
number required was fulfilled in each group. Patients were recruited from those
attending the HCT (HIV Counselling and testing) section and the ARV clinic. Sample
size was 150, with 50 individuals in each group.
3.4.4 Inclusion Criteria
 Patients 18-55 years of age.
 Subjects selected were divided into three sub groups.
 Group 1- Patients attending the HIV counselling and testing centre
(HCT) who had tested negative were invited.
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 Group 2 – Included in this group were patients attending the HIV
counselling and testing centre (HCT) who had tested positive and are
HAART naive. HIV positive patients attending the centre, who had a
CD4 count above 350 cells/mm3, and thus, not eligible for HAART,
were also allocated in this group.
 Group 3- This group consisted of HIV positive patients, from the ARV
clinic, who had been on HAART for 2 years or longer.
3.4.5 Exclusion Criteria
 Any patient who was on any other (other than HAART) acute or chronic meds that
have a side effect of xerostomia.
 Any patient who had been diagnosed with any auto immune salivary gland disease.
 Any patient who had received any head and neck radiation.
 Completely edentulous patients who were not using any dentures.
 Female patients who were pregnant.
 Any patient who was diagnosed with diabetes mellitus.
3.4.6 Data Collection and Procedure
All saliva collection was done between 9:00 am and 3:00 pm and the subjects were
asked to refrain from consuming food or fluids for 90 minutes before the procedure.
The volunteers were given a patient information sheet (Appendix 1-3) to take home
and the whole process was explained to them in English, Afrikaans or Xhosa, with the
help of an interpreter where necessary. A written consent (Appendix 4-6) in the
language of their choice was then obtained. The subjects were asked to rinse out their
mouth with tap water before saliva collection. A data collection form was used for
recording details from each patient (Appendix -7).
Sterile, graduated plastic tubes, with a funnel placed on top, were used for collecting
saliva (see picture 3.1& 3.2).
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The subject was asked to hold the tube and sit forward with the head bent down (see
picture- 3.3). A countdown timer was used to mark time elapsed.
Picture 3.1- Tube with funnel
Picture 3.2- Armamentarium for saliva collection
 
 
 
 
44
Picture 3.3- Patient positioning during saliva collection
Unstimulated whole-mouth saliva was collected by the “spitting method” into the tube
for 3 mins. At the end of three minutes, the tubes were collected and new tubes used
for collecting chewing stimulated saliva. A 2cm piece of sterile rubber (see picture -2)
was used for chewing and saliva collected by the same method. The subjects were
asked to chew for one minute and spit only the saliva into the tube. Keeping the rubber
piece in the mouth, the process was repeated two more times and the rubber discarded
separately. Chewing was regulated, to 45 strokes per minute, with the use of a
metronome (see picture-3.4). The tubes were capped and marked with the subject
number and a suffix “a” for resting and “b” for chewing stimulated samples.
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Picture 3.4- Android Application for a Metronome, set at 45 beats per minute
A xerostomia questionnaire (Appendix-8) was filled with the help of Xhosa or
Afrikaans- speaking translator when needed. This questionnaire is based on the four
questions found by Sreebny & Valdini (1988) to have a high specificity and predictive
value.
All saliva samples collected were weighed on a calibrated scale at the National Health
Laboratory Services, East London (NHLS). Since the specific gravity of saliva is one,
1 gram is considered equivalent to 1 ml. The weight of the empty tube was
predetermined and this was subtracted from the total weight. Each measurement was
then divided by 3 to obtain the flow rate per minute. This was recorded on the
subject’s saliva record (Appendix-9).
An unstimulated salivary flow rate measure of ≤ 0.16 ml/min is considered as
abnormal and a flow rate of ≤ 0.7 ml/min of stimulated saliva is considered as
abnormal (Navazesh et al., 2003). A positive response to any of the xerostomia
questions is considered as indicative of presence of xerostomia.
Since all the data was collected by a single examiner, inter-examiner variability was
avoided.
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3.5 DATA ANALYSIS
Data was captured on the forms and tabulated on Microsoft Excel. Data Analysis was
done with the statistical software “R” version 2.15.0 (2012-03-30) (Copyright © 2012,
The R Foundation for Statistical Computing).  The data collected was subjected to
descriptive analysis and prevalences were calculated. The significance of the
differences of prevalences were calculated by Chi-squared test and, where applicable,
Fischer’s exact test. Statistical significance was set at p- value <0.05.
The influence of independent variables such as sex, age etc. on xerostomia prevalence
was examined using logistic regression. Low resting and chewing stimulated salivary
flow rates were treated similarly.
The group differences in mean flow rates were examined by least squared linear
regression and associated analysis of variance (ANOVA). The student’s t- test was
used whenever differences between two mean flow rates needed to be analysed for
significance.
3.6 LIMITATION OF THE STUDY
3.6.1 Data Collection
Due to departmental (Dept of Health) policy, stable patients on HAART have their
CD4 counts taken only once a year. Hence, the latest available CD4 counts had to be
used; some of these were older than a year and were not included. Since Viral Loads
are routinely checked only at the time of HAART initiation and treatment follow-ups,
viral load measurements were not available for any of the patients in group-2. Viral
loads were available only for group-3 and 78% of them had a value lower than the
detectable level and only 2% had a count less than 1000 copies/ml. This made it vapid
to check the influence of viral loads on any of the outcome measures.
All saliva collection was done between 9:00 am and 3:00 pm. This wider time frame
was selected to allow for maximum participation by the patients that attend the facility
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and to allow for the data collector to attend to regular patients in between, since it was
not possible to set aside time only for data collection due to work commitments.
3.7 ETHICAL CONSIDERATION
Ethical approval was obtained from the Senate Research Committee, University of
Western Cape (Appendix-10). Permission to conduct the study was obtained from the
Department of Health, Eastern Cape (Appendix-11) and from the facility manager at
EGCHC.
Patient confidentiality was maintained at all times. Subjects were allocated study
numbers and names or personal details were not recorded anywhere on the data sheet.
Patients who recorded low saliva flow rates were given onsite oral hygiene
instructions as well as instructions to improve the saliva flow. Patients requiring dental
treatment were made aware of treatment needs and referred to the dental clinic.
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CHAPTER - 4
RESULTS
4.1 DEMOGRAPHIC DETAILS
The 150 participants were allocated into three groups; Group-1 was HIV negative
individuals; Group-2 HIV positive individuals who were HAART naive and Group-3
was HIV positive individuals who had been on HAART for more than 2 years. The
demographic distribution according to Groups is illustrated in figures 4.1 & 4.2.
Figure 4.1- Age distribution by group
Figure 4.2- Gender distribution by group
30 26
5
61
15 16
24
55
5 8
21
34
Group-1 Group-2 Group-3 Total
Age distribution by group
18-30 yrs 31-40 yrs 41-55 yrs
15 15 10
4035 35 40
110
Group-1 Group-2 Group-3 Total
Gender distribution by group
Males Females
(Mean age 30) (Mean age 32) (Mean age 39) (Mean age 34)
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Of the 150 patients, 40 (27%) were males and 110 (73%) were females. The average
age of male participants was 36 years and of female participants it was 33 years. The
average age of the whole study population was 34 years. The total number of smokers
were 17 (11%) with 8, 7 & 2 in groups 1, 2 & 3 respectively. Of these only 2 (1%)
patients, both in group-1, smoked more than 10 cigarettes per day (see table 4.1)
Table 4.1– Distribution by habit
Variables
GROUP-1
(N=50)
GROUP-2
(N=50)
GROUP-3
(N=50)
Total
(N=150)
Smoking (cig/day) <5 3        (6%) 3 (6%) 1 (2%) 7 (5%)
6-10 3        (6%) 4       (8%) 1 (2%) 8 (5%)
>10 2        (4%) 0 0 2 (1%)
Total 8      (16%) 7 (14%) 2 (4%) 17 (11%)
CD4 counts were recorded for groups 2 and 3. The CD4 counts of five subjects in
group-3 were missing or outdated for use. This was taken into consideration during
analysis. Group 2 had significantly more patients with CD4 counts ≤350 cells/mm3;
62% (n=31) of the patients in group-2 had a low CD4 count ≤350 cells/mm3 when
compared to 20% (n=9) in group-3. This is expected since the patients in group 3 had
been on HAART for more than two years. The mean CD4 count in group-2 was
338.66 (SD 288.26) cells/mm3 and that of group-3 was 577.06 (SD 266.54) cells/mm3.
78% of the patients in group-3 had a viral load that was Lower than Detectable Limit
(LTDL). Only one patient had a viral load greater than 1000 copies /ml. Viral load
measurements were not available for any of the patients in group-2.
In group-2, although the HIV positive patients were not on HAART, 6 (12%) of them
were on either Co-trimoxazole or Isoniacid (INH) and 2 of these were on both the
drugs. In group -3, 12 (24%) HIV positive patients were on INH or Co-trimoxazole in
addition to being on HAART. A complete tabulation of all the clinical data can be
seen in table 4.2
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Table 4.2- Distribution by clinical data
Variables
GROUP-1
(N=50)
GROUP-2
(N=50)
GROUP-3
(N=50)
Total
(N=150)
CD4
Count(cells/mm3)
≤350 Not
Determined
31     (62%) 9* (20%) 40 (42%)
>350 19     (38%) 36* (80%) 55 (58%)
Viral Load
(copies /ml)
LTDL
Not
Applicable
Not
Determined
39   (78%) N/A
≤1000 10 (20%) N/A
>1000 1      (2%) N/A
Taking Co-trimox
&/ INH
Yes Not
Applicable
6    12%) 12    (24%) 18   (18%)
No 44   (88%) 38   (76%) 82   (82%)
HAART regimen
FDC Not
Applicable
Not
Applicable
34  (68%) N/A
Other
HAART 16  (32%) N/A
* Five CD4 counts were not available in Group-3
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4.2 PREVALENCE OF XEROSTOMIA
The overall prevalence of xerostomia was 50% in the total study population. Group -2
showed the highest prevalence with 33 (66%) out of 50 subjects responding
affirmative to at least one of the xerostomia questions in the questionnaire.  25 (50%)
subjects and 17 (34%) subjects, in groups 1 and 3 respectively, responded similarly.
The differences in prevalences between the groups were examined using the Chi-
Squared test. The hypothesis of homogeneous prevalences was rejected at level 0.006.
The difference between group-2 and group-3 was found to be significant at p=0.002.
Although group-2 had a higher xerostomia prevalence than the HIV negative patients
in group-1, the difference between the two prevalences was not significant at p= 0.156.
Table 4.3- Prevalence of xerostomia among the groups
Outcome Group-1 Group- 2 Group-3 P value
Xerostomia 50% 66% 34% 0.006*
*Significant at p<0.05
Figure 4.3- Prevalence of xerostomia by group
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Table 4.4- Distribution of xerostomia scores according to number of questions
No: of
Questions
GROUP-1
(N=50)
(%)
GROUP-2
(N=50)
(%)
GROUP-3
(N=50)
(%)
TOTAL
(N=150)
(%)
Any
Question 25 (50%) 33 (66%) 17 (34%) 75 (50%)
1 Question 11 (22%) 13 (26%) 7 (14%) 31 (21%)
2 Questions 7 (14%) 10 (20%) 5 (1%) 22 (15%)
3 Questions 5 (10%) 6 (12%) 3 (6%) 14 (9%)
4 Questions 2 (4%) 4 (8%) 2 (4%) 8 (5%)
Table 4.4 shows the frequency of positive responses to each of the four xerostomia
questions. Question no-3 was the only one that showed a significant difference
between the questions and only in group-2 with p= 0.032. Table 4.5 shows the
distribution of the positive answers between the different questions.
Table 4.5- Distribution of the positive responses to the different xerostomia
questions
Xerostomia Questions GROUP-1 (N=50) GROUP-2 (N=50) GROUP-3(N=50)
1) Does your mouth
feel dry often? 12 (24%) 18 (36%) 9 (18%)
2) Do you regularly do
things to keep your
mouth moist?
17 (34%) 19 (38%) 12 (24%)
3) Do you get out of
bed at night to drink
fluids?
10 (20%) 20 (40%) 10 (20%)
4) Does your mouth
usually become dry
when you speak?
9 (18%) 10 (20%) 3 (6%)
The influence of covariates on the prevalence of xerostomia was examined by fitting
generalized linear models with the dependent variable xerostomia and independent
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variables Group, Age, Sex, Smoking, CD4 and use of C0-trimoxazole/ INH (using
only Groups 2 and 3). Multiple logistic regression analysis revealed that the significant
predictor besides group was age. Age was found to have a significant negative
correlation at p=0.002. The distribution of the prevalence according to the covariate
influence is tabulated in table 4.6
Table 4.6- Prevalence of xerostomia in the different groups and covariate categories
Co-variates
Group-1 (N=50)
(n)         %
Group-2 (N=50)
(n) %
Group-3 (N=50)
(n) %
Total (N=150)
(n) %
AGE (yrs)
18-30 17 (30)
56% 20 (26) 77% 3     (5) 60%
40 (61) 66%
31-40 6  (15) 40% 8   (16) 50% 10  (24) 42%
24 (55) 44%
41-55 2      (5) 40% 5     (8) 62% 4   (21) 19%
11 (34) 32%
Gender      M
7 (15) 47% 8  (15) 53% 1  (10) 10%
16 (40) 40%
F
18 (35) 51% 25 (35) 71% 16  (40) 40%
59(110) 54%
CD4(cell/mm3)
≤350 Not
Determined
21 (31) 68% 2   (9)* 22% 23(40)* 58%
>350
12 (19) 63% 14 (36)* 39% 26(55)* 47%
Use of
Co-trimox &/
INH
Yes
Not
Applicable
5    (6) 83% 7   (12) 58% 12 (18) 67%
No
28 (44) 64% 10  (38) 26% 38 (82) 46%
*Five CD4 counts were not available in Group-3
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4.3 PREVALENCE OF LESS THAN NORMAL RESTING FLOW
RATE
A resting flow rate (Flow Rate A) ≤0.1ml/min is considered as below normal
(Navazesh et al., 2003; Sreebny & Valdini, 1988). Of the 150 patients only 8 (5%) had
a flow rate –A that was ≤0.1ml/min. Of these 2 were from group -1, 5 from group-2
and 1 from group-3.  The prevalence of hyposalivation in resting flow rates among the
groups is shown in table- 4.7. There was no statistical significance to the differences in
prevalences as revealed by the Fisher’s exact test. The hypothesis of equal prevalence
for less than normal resting flow rate between groups could not be rejected at level
0.277
Table 4.7- Prevalence of less than normal (≤0.1ml/min) resting flow rate
Outcome Group-1 Group- 2 Group-3 P value
Resting Flow Rate
≤0.1ml/min
(Flow rate- A)
4% 10% 2% 0.277
Figure 4.4- Dot Plot for Resting Flow Rates (Flow Rate-A) by Group
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The influence of independent variables on the prevalence of less than normal  salivary
resting flow rates were analysed by logistic regression, Chi- squared and Fisher’s
exact tests.  None of them had statistical significance. The prevalence of less than
normal resting flow rate as influenced by the different co-variates can be seen in table-
4.8.
Table 4.8- Prevalence of less than normal resting flow rate (≤0.1 ml/min) in the
different groups with co-variates.
Co-variates
Group-1
(N=50)
(n) %
Group-2
(N=50)
(n)        %
Group-3
(N=50)
(n)        %
Total
(N=150)
(n) %
AGE (yrs)  18-30 1 (30) 3% 1 (26) 4% 0    (5) 0% 2 (61) 3%
31-40 1   (15) 6% 3 (16) 19% 0  (24) 0% 4 (55) 7%
41-55 0     (5) 0% 1 (8) 13% 1  (21) 5% 2 (34) 6%
Gender         M 0    (15) 0% 1 (15) 6% 0    (10) 0% 1 (40) 3%
F 2    (35) 6% 4 (35) 11% 1    (40) 3% 7(110) 6%
CD4 (cell/mm3)
≤350
Not
Determined
3 (31) 10% 0 (9)* 0% 3 (40)* 8%
>350 2 (19) 11% 1 36)* 3% 3 (55)* 6%
Use of Co-trimox
&/INH
Yes
Not
Applicable
2 (6) 33% 1 (12) 8% 3 (18) 17%
No
3 (44) 75% 0 (38) 0% 3 (82) 4%
*Five CD4 counts were not available in Group-3
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4.4 PREVALENCE OF LESS THAN NORMAL CHEWING
STIMULATED FLOW RATE
A chewing-stimulated flow rate (Flow Rate B) of ≤0.7ml/min is considered as below
normal (Navazesh et al., 2003). Of the 150 patients 63 (42%) had a flow rate-B that
was ≤0.7ml/min. As with the xerostomia and low resting flow rate trend, group-3,
showed the least frequency with 16 (32%) patients having a less than normal chewing-
stimulated flow rate. Group-1 had 19(38%) and group 2 had the most with 28 (56%).
The prevalence of hyposalivation in chewing stimulated flow rates among the groups
is shown in table- 4.9. There was a statistical significance in the differences in
prevalence between groups (p=0.041). The significance was even greater when
patients not on HAART (group-2) were compared to those receiving HAART (group-
3), p=0.013. The hypothesis of equal prevalence for hyposalivation among the groups
can be rejected here with regard to less than normal chewing stimulated flow rate.
Table 4.9- Prevalence of less than normal (≤0.7ml/min) chewing-stimulated flow
rate
Outcome Group-1 Group- 2 Group-3 P value
Chewing-Stimulated
Flow rate ≤ 0.7ml/m
(Flow Rate-B)
38% 56% 32% 0.041*
*Significant at p<0.05
Figure 4.5- Dot Plot for Chewing-stimulated Flow Rate (Flow rate – B) by Group
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Upon logistic regression analysis, apart from group, a low CD4 count was found to be
of significant (p=0.015) influence on the prevalence of a less than normal chewing-
stimulated flow rate.  A low CD4 count is described here as one that is ≤350cells/mm3.
Table 4.10- Prevalence of less than normal chewing-stimulated flow rate (≤0.7
ml/min) in the different groups with co-variates
Co-variates Group-1(N=50)
(n)                 %
Group-2(N=50)
(n)      %
Group-3(N=50)
(n) %
Total(N=150)
(n)              %
AGE (yrs)
18-30
11
(30)
37% 14 (26) 54% 3 (5) 60% 28 (61) 46%
31-40 5
(15)
33% 10 (16) 63% 7 (24) 29% 22  (55) 40%
41-55 3    (5) 60% 4    (8) 50% 6 (21) 29% 13 (34) 38%
Gender M 4
(15)
27% 7 (15) 47% 2  (10) 20% 13 (40) 32%
F 15
(35)
43% 21 (35) 60% 14 (40) 35% 50(110) 45%
CD4(cell/mm3)
≤350
Not
Determined
20 (31) 65% 4   (9)* 44% 24(40)* 60%
>350
8 (19) 42% 10(36)* 28% 18(55)* 33%
Use of Co-trimox
&/INH
Yes
Not
Applicable
4    (6) 67% 5   12) 42% 9  (18) 50%
No
24 (44) 55% 11 (38) 29% 35(82) 43%
*Five CD4 counts were not available in Group-3
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4.5 DIFFERENCE IN MEAN FLOW RATES
The availability of individual flow rates had made it compulsive to consider if there
was a significant difference in the mean flow rates between the groups. The mean
resting flow rates (Flow Rate –A) for each group was calculated and subjected to a one
way Analysis of Variance (ANOVA). Mean chewing-stimulated flow rates (Flow
Rate-B) were also treated in the same way.
There was a significant difference in both resting and chewing-stimulated flow rates
between the groups as seen in table-4.11. Figures 4.6 & 4.7 illustrate this difference
graphically. The difference in the means between Group-2 and Group-3 was more
significant with p=0.003 for resting flow rate and p=0.012 for chewing-stimulated
flow rates.
Table 4.11- Outcome measures for salivary flow rates
Salivary Flow Rates
GROUP-1
(N=50)
GROUP-2
(N=50)
GROUP-3
(N=50) p- value
Resting
(Flow Rate A)
Mean
(SD)
(ml/min)
0.53   (0.37) 0.42   (0.31) 0.66   (0.47) 0.010*
Median
(ml/min) 0.41 0.33 0.45 N/A
IQR 0.48 0.38 0.62 N/A
Chewing
Stimulated
(Flow Rate B)
Mean
(SD)
(ml/min)
0.96   (0.59) 0.81    (0.63) 1.14   (0.67) 0.034*
Median
(ml/min) 0.84 0.67 1.08 N/A
IQR 0.68 0.57 0.84 N/A
*Significant at p<0.05
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Figure 4.6- Mean resting flow rate by group
Figure 4.7- Mean chewing-stimulated flow rate by group
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4.6 CORRELATING PREVALENCE OF XEROSTOMIA WITH
MEAN FLOW RATES
Although, the prevalence of low chewing-stimulated flow rates did show a better
association to the xerostomia scores than resting flow rates, there was a general lack of
comprehensive association between the xerostomia scores and the prevalence of low
salivary flow rates. However, when the mean flow rates of those with a xerostomia
score of 1-4 was compared to the mean flow rates of those that had a xerostomia score
of 0, both resting and chewing stimulated flow rates showed a statistical significance
in their differences. See table 4.12.
Table 4.12- Correlating xerostomia with mean flow rates.
Mean Flow Rates Xerostomia (n=75)
ml/min (sd)
No xerostomia (n=75)
ml/min (sd)
p- value
(t-test)
Resting
(Flow Rate –A)
0.45 (0.33) 0.63 (0.44) 0.005*
Chewing stimulated
(Flow Rate –B)
0.80 (0.61) 1.14 (0.62) 0.0009*
*Significant at p<0.05
A negative correlation was observed between the mean resting flow rates and
xerostomia scores. The mean resting flow rates reduced as the xerostomia score
increased (see table 4.13).
Table 4.13-Correlating xerostomia scores with mean resting flow rates
Xerostomia Scores
Mean Resting flow rate
(Flow rate –A)
ml/min  (sd)
1 0.50 (0.28)
2 0.46 (0.37)
3 0.38 (0.42)
4 0.32 (0.28)
This correlation was not seen for mean chewing-stimulated flow rates.
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CHAPTER- 5
DISCUSSION
The HIV prevalence in the Eastern Cape is estimated to be 11.6%. The Buffalo City
Metro, under which Empilweni Gompo Community Health Centre falls, has a
prevalence of 13.6% (Shisana et al., 2014). The oral health status of the 100 HIV
positive patients included in this study is believed to be an appropriate reflection of the
HIV infected population in this Metro.
Many studies have linked salivary gland hypofunction and xerostomia to HIV
infection (Mandel et al., 1992, Yeh et al., 1988). Some studies have also linked anti
retroviral medication to low salivary flow rates and xerostomia (Navazesh et al., 2000;
Nittayananta 2010a)
In total, there were 150 patients who partook in this study. 73% of them were females
with 70% in Group -2 and 80% in Group -3. This significant disproportion was also
seen in the SA national HIV Prevalence, Incidence and Behaviour survey (Shisana et
al., 2014) and was attributed possibly to the differences in the health seeking
behaviour between the two sexes.
Saliva collection was done from 9:00 am to 3:00 pm so that circadian influences
would be minimised (Navazesh et al., 1992a).
The age of 55 was selected as a cut off age in this study to minimize any age related
influence on salivary flow rate (Flink et al., 2008). All patients were requested not to
drink or eat for 90 minutes before saliva collection to minimise the influence of
stimulus from mastication and food ingestion.
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5.1 PREVALENCE OF XEROSTOMIA AND LESS THAN
NORMAL SALIVARY FLOW RATES
The prevalence of xerostomia ranges widely. It is influenced by age, gender, systemic
conditions, medication and even nutritional status. In a large population based study,
Flink et al., (2008) reported the prevalence of xerostomia to range from 8% to 39%.
In the present study the HIV negative group (Group-1) had a prevalence of 50%. This
could be attributed to the fact that these subjects were patients seeking medical
treatment for some sort of acute condition or the other. Most of them were suffering
from the common cold, viral flu, etc. Although none of them were on any medication,
general ill health could have negatively influenced their salivary function temporarily.
The HIV positive group that were not on HAART (Group-2), were a mixed group of
those that were acutely ill leading to a recent diagnosis of immune deficiency and
those that were HIV positive but healthy enough not to warrant HAART initiation.
This group had the highest prevalence for xerostomia at 66%. The average CD4 count
of this group was 339cell/mm3.
Group-3 was made up of HIV positive patients who had been on HAART for more
than 2 years. Most of the individuals were generally otherwise healthy and attending
the health centre for monthly follow up and medication. The mean CD4 count for this
group was 577cell/mm3. They had the lowest prevalence for xerostomia at 34%. The
overall prevalence of xerostomia was 50% in the total study population.
In a similar study from Thailand by Nittayananta et al., (2010a), they found 32%
xerostomia among HIV negative individuals, 61% in HIV positive not on HAART and
39% in HIV positive individuals on HAART for more than 3years. In India, Pavithra
et al., (2013) reported a positive response for the question “Often my mouth feels dry”
as 36% among HIV positive patients not on HAART and almost 3% for these patients,
after 6 months of being on ARVs. In Brazil, 40% xerostomia was seen by Busato et
al., (2014) among HIV positive patients. A much lower prevalence was reported from
the USA by Silverberg et al., (2004). 6.9% for HIV negative individuals, 16.2% for
HIV positive not on HAART. It appears that this study also identifies with the higher
prevalences seen in developing countries.
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In this study, the difference in prevalences for xerostomia between the groups were
found to be significant at p= 0.006. The difference between group-2 and group-3 was
also found to be significant at p=0.002.
Low salivary flow rates among HIV positive patients have been reported in many
studies (Yeh et al., 1988; Atkinson et al., 1989b; Lin et al., 2001; Navazesh et al.,
2003). In this study ≤0.1 ml/min and ≤0.7 ml/min were used as the cut off for
establishing less than normal resting and chewing-stimulated flow rates respectively
among the subjects. Nittayananta et al., (2010b) reported a 35% prevalence for less
than normal resting flow rate and 16% for less than normal chewing-stimulated flow
rate among HIV positive individuals who were not on anti-retroviral treatment. A
prevalence of 17% and 11% were also seen in the same study for less than normal
resting and chewing-stimulated flow rate respectively among HIV negative
individuals. Some of the other studies that evaluated prevalence of low flow rates
reported the results as odds ratios (Navazesh et al., 2003; 2000). Hence, a comparison
could not be made to this study. In this study the prevalence of less than normal
resting flow rates were low in all three groups with group-2 showing the highest
prevalence at 10%. The difference in prevalences of less than normal chewing-
stimulated flow rate among the groups appear to be significant at p= 0.041. The HIV
positive group not on HAART (group-2) showed the highest prevalence at 56%;
followed by the HIV negative group (group-1) at 38% and the HIV positive group on
HAART (group-3) showed the least at 32%.
It would appear that, in this study, there is a consistency in the extent to which the
different groups are affected by xerostomia and hyposalivation, with group-2 showing
the most salivary incapacitation and group-3 showing the least salivary gland
dysfunction.
In many of the other studies related to evaluation of salivary flow rates, mean flow
rates were used for comparison of salivary hypofunction between groups (Navazesh et
al., 2009; Lin et al., 2006; Nittayananta et al., 2010a; Pavithra et al., 2013; Johar et al.,
2011). Due to differences in methodology and some of the studies being on mostly PI
based HAART regimen, a comparison to this study for mean salivary values was not
conclusive.
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5.2 OUTCOME MEASURES IN HIV POSITIVE INDIVIDUALS AS
INFLUENCED BY HAART
It is clear from comparing the outcomes for the two groups, that, not being on anti-
retroviral treatment puts HIV positive patients at risk for salivary gland dysfunction.
Table-5.1 lays this picture out clearly. This is in contrast to studies that have shown
HAART to be a risk for xerostomia and low salivary flow rates (Navazesh et al., 2003,
2009) and also to those studies that did not show any difference between HIV positive
individuals on HAART and not on HAART (Lin et al., 2006; Jainkittivong et al.,
2009; Johar et al., 2011; Pavithra et al., 2013).
Table 5.1- Prevalences and mean flow rates as influenced by HAART
Outcome Group -2(Non HAART)
Group -3
( HAART) P value
OR (CI)
Xerostomia 66% 34% 0.002* 0.269 (0.107,0.655)
Resting flow rate
≤0.1ml/m 10% 2% 0.204 0.186(0.004,1.757)
Chewing stimulated
flow rate
≤ 0.7ml/m
56% 32% 0.026* 0.374(0.151,0.900)
Mean resting flow
rate ( Flow rate-A)
ml/min
0.42 (0.31) 0.66 (0.47) 0.003* N/A
Mean Chewing-stim
Flow rate (Flow
rate-B) ml/min
0.81 (0.63) 1.14 (0.67) 0.013* N/A
*Significant at p<0.05
There was a decrease in salivary function and increase in xerostomic symptoms among
those HIV positive patients that were not on HAART. The difference in mean flow
rates between the groups was greater for resting flow rate than for chewing stimulated
flow rate. This indicates that the submandibular gland, which is responsible for about
65% of the resting salivary flow, is affected more in this group. Atkinson et al.
(1989b) have observed that in HIV positive individuals, the function of the
submandibular gland is affected earlier in the disease and the parotid is affected over
time.
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Among those on long term HAART, the stimulated salivary flow, to which the parotid
contributes more than 50%, appears to be more affected than resting salivary flow.
This could be due to the changes that HAART brings about upon the parotid gland.
Although the exact mechanism is unknown, accinar changes, lipomatous changes and
IRIS have all been proposed (Navazesh et al., 2003; Olive et al., 1998; Greenspan et.
al., 2001)
In a study by Pavithra et al. (2013), the longitudinal effect of the drug regimen
2NRTI’s + 1 NNRTI on salivary gland function was evaluated. No significant
differences were noted in the flow rates between those on HAART and those not on
HAART at baseline. However, there was an increase in flow rate and decrease in
xerostomia complaints as the duration of HAART increased up to 6 months. In this
study 68% (n=34) were on the Fixed Drug Combination pill (FDC - 2NRTI’s +
1NNRTI). When comparing the outcomes of those on this regimen with those on other
drug regimens, although not significant, there was an increase in the prevalences of
xerostomia and hypofunction. A significant reduction was seen in the mean chewing
stimulated flow rate (Flow Rate- B) for those on FDC; p= 0.034; when compared to
those on other HAART regimens; illustrated in figure -5.1
Figure 5.1- Mean chewing-stimulated flow rates - FDC Vs Other HAART
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This could be due to the fact that apart from 2 of the 34 subjects that were on FDC, the
majority of them had changed their HAART regimen in the past 6 months. Silverberg
et al., (2004) & Navazesh et al., (2009) had found in their study that patients on stable
HAART usage had higher salivary flow rates and lesser xerostomia complaints than
those that switched HAART or discontinued treatment in the previous 6 months. There
was no significant difference in the xerostomia prevalence between these two groups.
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5.3 Influence Of Other Variables
Imitating most of the other studies (Sreebny & Valdini, 1988; Narhi, 1994; Nederfors
et al., 1997; Farsi, 2007; Flink et al., 2008), the prevalence of xerostomia was higher
for females than males but not statistically significant at 54% Vs 40%. This trend was
seen for the prevalence of less than normal resting and chewing stimulated flow rates.
When mean flow rates were compared, males had a significantly more chewing
stimulated flow rate than females, 1.18 ml/min Vs 0.91ml/min; p=0.031. Torres et al.,
(2002) also found a significant difference in the chewing stimulated flow rates
between males and females. The reason for increased volumes of saliva produced by
males could be explained by the findings by Scott (1975); males had up to 50% larger
submandibular glands than females.
Unlike many other studies that associated increasing age with increasing xerostomia
complaints (Flink et al., 2008; Nederfors et al., 1997; Sreebny & Valdini, 1988), there
was a negative correlation between the two in this study; p=0002. Although not
significant, this negative correlation was also seen for mean chewing stimulated flow
rate. This could be because the range of ages included here; 18-55 years; do not
significantly affect xerostomia and the influence is coincidentally due to other
systemic factors. According to Flink et al. (2008) the prevalence of xerostomia and
hyposalivation did not vary much until the age of 50 years for women and 60 years for
men.
While low CD4 counts (<200 cell/mm3) has been attributed as a significant risk factor
for xerostomia and hyposalivation by many authors (Navazesh et al., 2000, 2003,
2009), some did not find this correlation significant (Nittayananta et al., 2010a;
Pavithra et al,. 2013; Lopez-Verdin et al., 2013). According to Schiødt et al., (1992)
the reduction in salivary flow is “likely to be a function of the degree of inflammatory
infiltrate in the gland but not associated with degree of immune deficiency”. In this
study,  CD4 counts ≤ 350 was used as the criteria for low CD4 count since this is the
level at which HAART is initiated in the South African Public Health system.
Xerostomia prevalence did not show a significant difference between the two CD4
groups. A statistical significance was found only in the prevalence of less than normal
chewing stimulated flow rate with p=0.015 and not in the prevalence of less than
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normal resting flow rate. When mean flow rates were compared, although, the flow
rates were reduced in those with CD4 counts ≤350 cell/mm3, there was no statistical
significance. The difference in mean resting flow rates came close to significance at
p= 0.057.
The mean resting flow rate for those with CD4 counts ≤350 cell/mm3, when calculated
in Group-2 alone, was found to be significant at p= 0.036. This, further points to the
oral health vulnerability of these HIV positive patients with a low CD4 count in whom
HAART is yet to be initiated and during the period while waiting for the therapeutic
effect of HAART to improve the CD4 count.
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5.4 CORRELATING THE XEROSTOMIA SCORES WITH THE
FLOW RATES
Some of the previous studies (Fox et al., 1987; Thomson et al., 1999b; Narhi et al.,
1994) did not find a significant correlation between xerostomia complaints and
prevalence of low salivary flow rates. Dawes (1987) had reported that xerostomia
complaints were seen only after there was a 40% -50% reduction in the actual salivary
flow rate. On the other hand, xerostomia complaints can be made in the absence of
actual reduction of flow rate due to the systemic and physiological factors affecting the
perception of dry mouth.  Xerostomia complaints were seen to be increased in subjects
who were dehydrated (Ship & Fischer, 1997).
In this study, a significant association could not be made between the prevalence of
xerostomia and that of low flow rates as assessed by pre-determined cut-off values;
≤0.1 ml/min for resting flow rate and ≤0.7 ml/min for chewing stimulated flow rates.
However, using the student’s t-test, when the mean flow rate of those that complained
of xerostomia was compared to the mean flow rate of those that did not complain of
xerostomia, a significance was found both in resting flow rates (p=0.005) and chewing
stimulated flow rates (p=0.0009). See figures 5.2 & 5.3.
Figure 5.2- Mean resting flow rates - Xerostomia Vs No Xerostomia
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Figure 5.3- Mean chewing-stimulated flow rates - Xerostomia Vs No Xerostomia
This lack of consistency in the association of xerostomia to prevalence of low flow
rates and xerostomia to mean flow rates could be due to the possibility that the cut –off
values for calculating the prevalence of low flow rates were not compatible with the
salivary attributes of this population. Further large scale studies would be necessary to
establish criteria appropriate for the South African population.
The negative correlation seen between xerostomia scores and mean resting flow rates
is expected since the questions used in this study are more reflective of salivary
perceptions during rest rather than during function.
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Chapter-6
CONCLUSION
Salivary gland dysfunction is observed more readily in those that are
immunocompromised and not yet on HAART. Special attention should be paid in
planning an intense prophylactic treatment regimen to prevent and manage the oral
conditions that are associated with reduced salivary flow in these individuals.
HAART in itself does not appear to adversely affect xerostomic perceptions or
salivary flow rate. The improved immunity that comes from being on Anti Retroviral
treatment is beneficial to salivary gland function.
Duration of HAART, change in regimen, type of regimen, all seem to have an effect
on salivary flow rate (Silverberg et al., 2004; Lopez- Verdin et al., 2013; Navazesh et
al., 2009).  Thus, studies on larger samples and of longitudinal design are necessary to
explore the possibility of similar findings in the South African context. This would in
turn further pin point those vulnerable to salivary hypofunction and its effects,
enabling timeous prophylactic actions.
Salivary flow rate is influenced by inter and intra individual variations. Most of the
large scale studies that were done to establish criteria for determining the presence of
glandular hypofunction were conducted in first-world circumstances and might not be
adequate for the South African population. There were instances in this study where a
significance was found in mean flow rates but not in prevalences of less than normal
flow rates (as dictated by cut-off values) when compared for the same situation. This
indicated that mean flow rates are possibly better indicators of the salivary function of
a population where the cut –off values were not established through bespoke studies
for that population. Further large scale studies are needed to establish the cut –off
values appropriate for this population.
The xerostomia questionnaire appears to be a useful tool in indicating those with low
salivary flow rates, especially resting flow rates. Studies that evaluate its specificity
and sensitivity are necessary before further endorsement.
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CHAPTER-7
RECOMMENDATIONS
 All newly diagnosed HIV positive patients should be referred to the dentist for
examination and establishing baseline oral conditions. Other health care
workers involved in the diagnosis and management of the HIV positive patient
should be made aware of the influence that the state of immune suppression
and HAART status has on salivary gland function. Enough emphasis cannot be
made on the effect that oral health status has on the general well-being and
quality of life of an individual.
 Patients showing signs and symptoms of salivary dysfunction should be tested
for salivary flow rates and managed with intense prophylactic emphasis.
 Support for longitudinal studies that can further evaluate the long term impact
of HAART on oral health.
 Support for large scale studies that can help in evaluating salivary function
norms for the South African population and thus help in formulating relevant
xerostomia and salivary flow diagnostic measures. This would then pave the
way to formalise guidelines for the management of salivary gland dysfunction.
These management strategies should include cost effective regimens that will
be accessible to all sectors of the South African population.
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CHAPTER-9
APPENDICES Appendix-1
PATIENT INFORMATION
Dear Mr/Mrs/Ms _________________________________
Thank you for agreeing to take part in the study.
Before we proceed, please ensure that your last meal, drink and or cigarette have been
at least 90 mins or more ago. I will be asking you a few questions and will write down
your answers. If you need further explanation at any point please do not hesitate to
ask. After the questions we will begin the process of saliva collection. Saliva will be
collected twice from you as explained below:
 Please sit and relax for 5 mins before we start.
 Please rinse your mouth with the water provided before we start.
 Saliva at rest: collection time is 3 mins.
You will be given a tube fitted with a funnel. Please allow saliva to collect in
your mouth and gently spit into the funnel every minute. You will be notified
of the time. At the end of 3 mins, spit all the saliva into the funnel to
completely empty your mouth.
 Rest for 5 mins.
 Saliva under stimulation: collection time is 3 mins.
You will be given a new tube with a funnel. This time you will be given a
piece of rubber to chew on and   you will spit only the saliva gently into the
tube every 1 min. Chewing will be at the rate of 45 stroke per minute keeping
in time with a sound you will hear. You will be informed at the end of each
minute to spit. At the end of the 3 mins, spit the saliva into the funnel to
completely empty your mouth of saliva.
 You may discard the piece of rubber, rinse out your mouth and clean up
Thank you kindly for your participation in our effort to improve knowledge in the oral
health field. If you have any questions or queries or would like more information,
please contact Dr Cherian on 0437331289. Have a good day further.
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INKCUKACHA Appendix- 2
Mr/Mrs/Ms _________________________________
Ndiyabulela ngokuba uvumile ukuthabatha inkxhaxheba koluphando.
Uncede ungatyi, ungaseli kwaye ungatshayi iyure enesiqingatha phambi kokuba
siqale. Ndizakubuza imibuzo endakuthi impendulo zakho ndizibhale phantsi, ukuba
ufuna ingcaciso ethe vetshe ungalibazisi ukubuza. Emveni kwemibuzo
ndizakuqokelela amathe akho. Amathe akho azakuqokelelwa kabini njengokuba
kuchaziwe apha ngezantsi. Ndicela uhlale phantsi, uphumle imizuzu ibemihlanu
phambi kokuba siqale.
 Xukuxa ngalo manzi alapho phambi ko kuba siqale.
 Sizakuthabatha imizuzu emithathu siqokele amathe akho ngokuziphumela
kwawo emlonyeni wakho. Uzakunikwa umbhobho onefanele. Nceda uvumele
amathe aqokelelane emlonyeni wakho emva koko uwathufele apha kwifanele
qho emva komzuzu omnye. Sizakwazisa xa kuphela umzuzu.. emveni
kwemizuzu emithathu, nceda uthufele kwifanele onke amathe asemlonyeni,
kungashiyeki mathe.
 Phumla ke imizuzu emihlanu.
 Sizakuthabatha imizuzu emithathu siqokele amathe akho ngokuthi siwabizele
ngokwethu. Uzakunikwa ifanele entsha kwakhona. siphinde sikunike intwana
encinci ye rubber omawuyihlafune uze qho emveni komzuzu uthufe amathe
odwa. Uzakuhlafuna qho xa usiva isandi esakuthi sisikhalise kanga mathuba
amashumi amane anesihlanu emzuzwini.  sizakwazisa xa  ilixesha lokuthufa
emveni komzuzu omnye. xa kuphele imizuzu emithathu thufela onke amathe
asemlonyeni wakho.
 Sigqibile ngoku kwaye ungawuhlamba umlomo wakho uzicoce.
Ndiyabulela kakhulu ngokuba uyewathatha inxhaxheba ekuphuhliseni iziko
lwezempilo lwamazinyo. Ukuba unemibuzo okanye kukho izinto ongathanda
ukuziqonda, nditsalele umnxeba kulenombolo 043 7331289.
Ulonwabele usuku lwakho.
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INLIGTING Appendix-3
Mnr. /Mev  _________________________________
Baie dankie dat u  ingestem het om deel te neem aan die studie. Maak seker dat jy
meer as n uur en n half laas iets geeet, gedrink of gerook het. Ek gaan u n paar vrae vra
en u antwoorde neerskryf, vra asseblief as ek enige iets weer moet verduidelik. Nadat
ek die vrae gevra het kan ek die proses begin om die speeksel te neem, soos ek
hieronder verduidelik.
 Sit asseblief nou en ontspan vir 5 min voordat ons begin.
 Spoel asseblief jou mond uit met die water.
 Speeksel toets: tyd vir opname is 3 min.
 Jy gaan n buisie met  n tregter kry. Laat die speeksel versamel in jou mond en
versigtig spoeg die speeksel in die buisie na elke minuut. Jy sal gese word van
die tyd. Na die einde van die 3min, spoeg al die speeksel in jou mond uit in die
buisie.
 Rus nou vir 5 min.
 Speeksel  onder stimulasie: tyd is 3 min. Jy gaan n nuwe buisie en tregter kry.
Hierdie keer gaan ons vir jou n stukkie rubber gee om aan te kou en dan na
elke 1 min versigtig in die tregter spoeg. Luister na die klank van die horlosie
en kou elke keer as die horlosie tik. Jy sal gese word om na elke min versigtig
die speeksel uittespoeg. Na 3min spoeg al die speeksel in jou mond uit in die
buisie.
 U kan nou u mond uitspoel.
Baie dankie vir u deelname in hierdie studie en om kennis van mond gesondheid te
verbeter. As u enige navrae of meer inligting wil he, kontak asseblief vir Dr. Cherian
by 043 7331289.
Geniet die dag verder.
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INFORMED CONSENT FORM Appendix--4
Patient No: ___________
Good day Mr/Mrs/Ms ____________________________
I am Dr Anney Cherian and I am a dentist at Empilweni Gompo Community Health
Centre. I am also a Masters student at dental faculty of the University of Western
Cape. I would like to invite you to take part in my research/ study. The study is to see
if there is a relationship between dry mouth and HIV medication. It will involve
answering a few questions and collecting your saliva (spit) in a tube. It will take about
20 -30 mins.
All information collected from you will be held confidentially and will be filed under a
code number that has been allocated to you. Your name will not appear on any form.
You are completely free to agree or decline this opportunity to be involved in this
study or not to take part in the study with no consequence to your treatment or care at
this facility.
If you have any questions or queries or would like more information, please contact Dr
Cherian on 0437331289.
If you would like to participate please sign the consent form below.
I acknowledge that this study has been explained to me and understand what the study
is about and would like to take part in it. I also understand that the results will not
disclose my identity and results used or published will be for the benefit in the
medical/ dental field.
Name: ________________________ Signature: ________________ Date:_________
Witness: ______________________ Signature: ________________ Date:_________
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IFORMU YEMVUMELVANO Appendix- 5
Patient No: _________
Molo  Mr/Mrs/Ms ____________________________
Igama lam ngu Anney Cherian ugqira wamazinyo Empilweni Gompo. Ndikwa
ngumfundi we zifundo eziphakamileyo kwicandelo lwezifundo zamazinyo kwi
University yase Ntshona Koloni . Ndiyakucela undincedise ngokuthatha inxhaxheba
kwizifundo nophando endilwenzayo. Sizama ukuphanda ukuba ingaba bukho na
ubudlelwane phakathi kwamachiza okunyanga intsholongwana kaGawulayo no koma
komlomo kwabo bawasebenzisayo.
Uzakundincedisa ngokuphendula imibuzwana nje embalwa nangokunikezela
ngamathe akho. Sizakuthatha imizuzu engamashumi amabini uyokutsho kumashumi
amathathu.
Yonke inkcazelo yakho neziphumo esizifumeneyo  ayizokupapashwa nakubani,
iyakugcinwa ikhuselwe phantsi kwe nombolo enikezwe wena kuphela. Igama lakho
alizokubhalwa kulamaphepha emibuzo.
Ukhululekile ukuba uthathe inxhaxheba koluphando okanye wale, lilungelo lakho.
Ukuba unemibuzo okanye kukho izinto ongathanda ukuziqonda, nditsalele umnxeba
kulenombolo 043 7331289.
Ndicela usayine apha ngezantsi ukuba uyavuma ukuthatha inxhaxheba.
Ndiyavuma ukuba ndicaciselwe ngoluphando kwaye ndiyaluqonda ukuba lungantoni.
Ndiyavuma ukuthatha inxhaxheba. Ndiyayiqonda nento yokuba iziphumo zoluphando
azizokupapashwa negama lam kwaye iziphumo zizakusetyenziselwa ukuphuhlisa
imfundo kwicandelo lezempilo nelamazinyo.
Igama: _______________________  Sayina: ________________Umhla:__________
Igama leingqina:________________ Sayina:________________ Umhla:__________
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INLIGTINGS VORM Appendix- 6
Patient No:_________
Mnr/Mev____________________________
My naam is Dr. Anney en ek is n tandarts by Empilweni Gompo Gemeenskap
Gesondheid kliniek. Ek is n Meestersgraad student aan die Tandheelkunde fakulteit
van die Universiteit van die Wes Kaap. Ek wil u graag uitnooi om deel te neem aan
my studie/navorsing. Die studie gaan oor die verwantskap tussen droe mond en HIV
medikasie. Dit sal beteken dat u n paar vrae moet beantwoord en n monster van u
speeksel moet geneem word. Dit sal omtrent 20 – 30 min van u tyd neem.
Die inligting wat ek neem sal as konfidentieel hanteer word  en net as n nommer teen
u naam verskyn. U naam sal nie op enige vorms verskyn nie.
U deelname aan die studie is vrywillig en sal nie  negatiewe gevolge he op die gehalte
diens en behandeling wat u ontvang by die kliniek nie.
As u enige navrae of meer inligting wil he, kontak asseblief vir Dr. Cherian by 043
7331289.
As u wil deelneem aan die studie, teken asseblief die aangehegte toestemmings  vorm
onderaan.
Ek erken dat die studie aan my verduidelik is, waaroor dit gaan en sal graag daaraan
deelneeem. Ek verstaan ook dat die resultate nie my identiteit sal weergee nie en dat
dit net vir mediese navorsing gebruik sal word.
Naam:___________________   Handtekening:_______________ Datum:________
Getuie:___________________  Handtekening: _______________ Datum:________
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DATA COLLECTION FORMS Appendix- 7
GENERAL QUESTIONAIRE
Pt No:________
Patient Number:_______________________________
Date:________________
Referred from: ___________________
1. Age___________years
2. Gender:  Male / Female
3. Last meal, drink, smoke _________________
4. Do you smoke: (Uyatshaya) (Roker) : Yes / No
5. If yes, how many cigarettes do you smoke in a day? (Ukuba uyatshayautshaya
izigarethi ezingaphi ngosuku?) (As ja, hoeveel sigarette rook u per dag?)  < 5  /
<10   /   >10
6. HIV Status:__________________  Since: ____________
7. CD4 Count (nearest available) _______________ Date Taken ____________
8. Viral load (nearest available) ________________ Date Taken _____________
9. Are you currently on medication for HIV?   Yes / No
(Ingaba usebenzisa amachiza okunyanga ugawulayo?) (Is U tans op medikasie
vir HIV?)
If yes, dated started: ( Uqale nini?) (As ja, watter datum?) _______________
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Pt No:________
10. Details of HIV medication: Bactrim     Yes/ No
IPT             Yes/ No
HAART       Yes/ No.
Any other Yes/ No
11. Details of  HAART:_______________________________________________
12. Have you tested Positive for TB?: (Ingaba wakhe wafunyaniswa une TB) (Het
U getoets vir TB, is die toets positief ) :  Yes/ No
If yes, when (Ufunyaniswe nini?) (As ja, watter datum?)
____________________
13. Are you currently taking medication for TB: (Ingaba usebenzisa amachiza
okunyanga TB  ngoku?) (Is U tans op medikasie vir TB?):  Yes/ No
If yes, date started: (Ukuba kunjalo, uqale nini ukuwasebenzisa) (As ja,
wanneer begin) _________________
14. Are you currently taking any other medication: (ingaba akhona amanye
amachiza ekungabe uyawasebenzisa ngoku angachazwanga apha) (Neem U
tans enige ander medikasie?) : Yes/ No
If yes, details. (Khawusiphe inkcazelo) (As ja,
besonderhede)___________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
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Pt No:________
15. Have you ever defaulted or stopped taking any medication on your own: Yes/
No
(Wawukhe waziyekela ngokokwakho ukusebenzisa amachiza ungayalelwanga
ngu mongikazi okanye ugqira?) (Het u enige tyd self  gestop om van die
medikasie te gebruik en later dan weer begin?)
If yes, details (Khawusiphe inkcazelo)(As ja,
besonderhede)___________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
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Appendix- 8
Pt No:________
XEROSTOMIA QUESTIONAIRE
1. Does your mouth feel dry often?                                                 Yes  / No
Uwuva umlomo wakho womile  rhoqo?
Voel jou mond gereeld droog?
2. Do you regularly do things to keep your mouth moist?            Yes  / No
Ingaba uzifumana amaxesha amaninzi usenza amalinge okugcina umlomo
wakho umanzi ukunqanda ukoma?
Doen jy gereeld iets om jou mond klam te hou?
3. Do you get out of bed at night to drink fluids?                         Yes  / No
Ukhe uzifumane uvuka ebusuku ukuze ufumane into yokusela?
Staan jy op gedurende die nag om vloeistof te drink?
4. Does your mouth usually become dry when you speak?          Yes  / No
Ingaba umlomo wakho uyoma xa  uthetha?
Droog jou mond uit wanneer jy praat?
XEROSTOMIA SCORE: ___________________
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Appendix- 9
Pt No:________
SALIVA RECORD
1. Unstimulated saliva (3 mins): Total weight:              _____________gms
Net weight of saliva:   ____________gms
Flow rate:                   ____________ml/min
2. Stimulated saliva (3 mins):     Total weight:              ____________gms
Net weight of saliva:   ____________gms
Flow rate:                   ____________ml/min
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Appendix- 11
 
 
 
 
